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ABSTRACT 
Despite global efforts, a preventative HIV vaccine remains elusive. The 
correlates of protection against HIV infection are as yet undefined, but clues can 
be drawn from potent antibodies able to neutralize diverse HIV strains. A series 
of potent broadly-neutralizing HIV antibodies have recently been isolated from B 
cells of HIV-infected individuals. VRC01 represents a subset of these antibodies 
that mediate neutralization with a restricted set of IGHV genes. The memory B 
cells that expressed these antibodies were isolated years after infection. 
Therefore, the B cell subpopulation from which they originated and the extent of 
participation in the initial HIV antibody response, if any, is unclear. Here, we 
evaluated the frequency of anti-gp120 B cells in follicular (FO) and marginal zone 
(MZ) B cell compartments of naïve wild type mice and the comparable human 
populations in uninfected individuals. We find that in HIV-unexposed humans and 
mice, the majority of gp120-reactive B cells are of naïve or FO phenotype, 
respectively. In a vaccine setting using HIV viral-like particles in alum, FO B cells 
appear to be the dominant anti-g120 responders. Unchallenged murine FO B 
cells express a diverse antibody repertoire to recognize gp120. In contrast, 
mouse MZ B cells recognize gp120 less frequently but preferentially use IGHV1-
53 to encode gp120-specific antibodies. These germline antibodies are 




to human IGHV1-2*02, which has repeatedly been found to encode broadly-
neutralizing mutated HIV antibodies, such as VRC01. Finally, we show that 
human MZ-like B cells express IGHV1-2*02 and that IGHV1-53 expression is 
enriched in mouse MZ B cells. These data suggest that efforts towards an HIV 
vaccine might consider eliciting protective HIV antibody responses selectively 
from alternative B cell populations harboring IGHV gene segments that are 
capable of producing protective antibodies. 
 
The form and content of this abstract are approved. I recommend its 
publication. 
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History of HIV  
Although the first cases of Acquired Immunodeficiency Syndrome (AIDS) 
were reported in 1981 [1], the virus that we now know as the human 
immunodeficiency virus-1 (HIV) crossed into humans half a century before that, 
and more than once [2]. Based on viral phylogenetics, HIV most likely came into 
the human population from the chimpanzee Pan troglodytes troglodytes [3]. 
Figure 1.1 shows the predicted zoonotic events for HIV. The main (M) group 
viruses that are responsible for the majority of the AIDS epidemic were likely 
from a single transmission event followed by viral diversification in the new 
human host. The exact mechanism of zoonosis is unknown, but speculation 
suggests that the virus may have crossed over from activities involving simian 
immunodeficiency virus (SIV)-infected primate blood during hunting or 
butchering, or consumption of contaminated meat from bush markets [4]. 
Contemporary and historical viruses have been sequenced for phylogenetic 
analyses. Molecular clock algorithms were then applied to generate an estimate 
of the original transmission event of the M group viruses. Two independent 
groups examined samples from 1959 and 1960 Kinshasa, the epicenter of the 
epidemic [5, 6]. These samples already showed a genetic distance in the HIV 
2 
 
envelope protein gp120 that is consistent with between-subtype comparisons, 
indicating that viruses circulating in Kinshasa were diversified and had already 
been present for several decades. The best estimates from each group placed 
the transmission event somewhere between 1908 to 1941, with their most 
confident predictions of somewhere around 1930. 
 
                     
Figure 1.1: Zoonosis of HIV-1.  
Shown here is a representation of the zoonosis of SIVcpz from Pan troglodytes 
troglodytes into Homo sapiens. Black arrows indicate individual transmission 
events, red lines indicate viral diversification in Homo sapiens. Adapted from 
Hahn 2000 [4]. 
 
 
How did the virus spread to become the global epidemic that is today? 
The answer may lie in events taking place in Africa in the early twentieth century, 
when much of equatorial Africa was under French colonial rule. There was much 
social upheaval and urbanization at that time, including work camps and 
prostitution, that would have lent itself to increased transmission of blood-borne 
diseases [4, 7]. In a campaign against smallpox, approximately 80,000 people 
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were vaccinated with live vaccinia. Before the advent of the dry vaccine, to 
transport the vaccine into central Africa, arm-to-arm transmission was likely used 
for at least 35,000 people [8]. Another health campaign against sleeping sickness 
in the 1920s and 1930s led to the treatment of almost 90,000 people with only six 
syringes [7]. Medical practices such as these could have certainly encouraged 
the spread of a novel disease that may not have been fully adapted to its new 
host. 
Over 30 years after its discovery and isolation, HIV is still a global health 
burden. Approximately 33 million people are infected with HIV worldwide and 2 
million people die each year from AIDS-related causes [9]. Although anti-
retroviral therapies have saved countless lives, these strict medical regimens 
must be carried out for the patient’s entire life and are often not available where 
they are needed most. Despite global scientific efforts, a preventative vaccine 
remains elusive. 
 
HIV vaccine attempts 
In 1983, concurrent papers published from different groups reported HIV 
as the causative agent of AIDS [10, 11]. A few months later, the NIH announced 
that a vaccine would be in reach in just another two years, a promise that 
obviously was not fulfilled. As all currently FDA-approved vaccines mediate 
protection through circulating antibodies [12], a classical subunit approach was 
initially taken to generate neutralizing antibodies to HIV. Neutralizing antibodies 
to the virus are directed to the two envelope glycoproteins, gp120 and gp41, 
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which are noncovalently associated in a trimeric spike (Fig 1.2). gp120 is 
responsible for binding to CD4 and subsequent coreceptor binding to CCR5 or 
CXCR4, while gp41 forms a hairpin to mediate fusion into the target cell. As gp41 
forms the “stalk” of the spike, gp120 is more exposed to the humoral immune 
system.  
 
Figure 1.2: The envelope glycoproteins of HIV.  
The envelope proteins of HIV, gp120 and gp41, noncovalently associate to form 
a trimeric spike. “gp120” refers to the monomer, whereas a trimer of gp120 
subunits is referred to as gp140. 
 
The first vaccine tested in humans was recombinant HIV envelope protein 
produced in insect cells [13]. In this vein, monomeric gp120 in a variety of 
adjuvants (e.g. alum, MPL) was used in various clinical trials into the early 
twenty-first century [14-16], without any production of long-lasting neutralizing 
antibodies. However, trials continued and one formulation by VaxGen advanced 
to phase III clinical trials. There was no protection from HIV infection or lowering 
of viral titers in those that became infected after receiving the vaccine. These 
studies culminated in what Spearman describes as “a clear and convincing 
failure” to protect against HIV [17]. Looking back, there are several reasons why 
these monomeric gp120 vaccines failed. The recombinant gp120 was partially 
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derived from a lab-adapted CXCR4-tropic strain [18], which is more susceptible 
to antibody neutralization than primary strains. Structural studies have also 
revealed that epitopes on the native envelope trimer are not always presented on 
monomeric gp120 [19].   
Other vaccine platforms early on focused on HIV envelope proteins 
expressed in the context of vaccinia virus but failed to elicit strong CD8 immune 
responses [20-23]. As HIV preferentially infects activated CD4 T cells [24, 25], a 
long-pondered hypothesis is that it may actually be detrimental to have a pool of 
expanded memory CD4 T cells to meet HIV without CD8 T cells; this has recently 
been confirmed in primate studies [26, 27]. Following the disappointment of 
monomeric gp120 to produce neutralizing antibodies, the vaccine field was 
revitalized with the notion that CD8 T cells were the answer to the HIV vaccine 
question. Recombinant vector platforms aimed at eliciting cellular immunity then 
took center stage. Preliminary results from the Merck Phase IIb STEP trial in 
2008 were quite discouraging [27, 28]. This vaccine regimen involved an 
adenovirus (Ad5) vector expressing a variety of internal HIV proteins. The data 
indicated that subjects that had high pre-existing antibodies against the Ad5 
vector were more susceptible to HIV infection than the placebo group. The trial 
was halted immediately and the NIH called for a refocusing of HIV vaccine 
research. A retroactive study using this vaccine platform in primates also failed 
viral challenge or lowering of viral setpoints [29]. 
The only vaccine that has shown any efficacy of lowering infection risk 
was a prime-boost regimen with a canarypox vector and recombinant gp120 from 
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previous trials. The results of the RV144 phase III trial showed a potential 31% 
efficacy [30]. T cell responses were generally weak, and anti-gp120 antibody 
responses were present but waned 90% in 20 weeks. The immunogenicity profile 
from vacinees is still being studied, but antibody-dependent cellular cytotoxicity 
(ADCC) may correlate with protection [31], as well as IgG antibodies that bind 
certain variable loops of the HIV envelope protein [32]. 
What these past few decades of HIV research have conclusively taught us 
is that antigen design and structure are of paramount importance. Even tabling 
the issues of inter-strain antigenic diversity, creating a structurally sound antigen 
that will promote binding to the native envelope trimer is a challenge [19]. One 
alternative would be to use inactivated HIV. This is considered too dangerous for 
preventative vaccines, but studies are underway to assess the effectiveness as 
therapeutic vaccines [33, 34]. A safer and immunogenically appealing alternative 
is viral-like particles (VLPs). VLP-based vaccines are already commercially 
available for Hepatitis B and human papilloma virus and are under consideration 
for influenza [35]. VLPs are non-replicative particles that still present antigens in 
their physiologically relevant formation. VLPs are genomeless and therefore non-
infectious and non-pathogenic. When the genes of viral structural products are 
expressed by transfection in primate cell lines, VLPs spontaneously form and 
bud out of the cell just as an infectious particle would, complete with host-derived 
membrane (Fig 1.3) [36]. VLPs can then be harvested from the supernatant and 
used as antigens. Although the viral proteins are in a native structure, the non-
infectiousness of the VLPs leads to a lack of TLR engagement and interferon 
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production. Thus, they must be supplemented with adjuvant to generate a robust 
immune response [37]. 
 
 
Figure 1.3: Schematic of VLP plasmid.  
When these gene products are expressed in mammalian cell lines, viral-like 
particles (VLPs) spontaneously form and bud out of the cell. HIV genes are 
written in italics. Safety mutations are shown as asterisks; deletions as “X”. 
Adapted from Young 2004 [36]. 
 
 
We, and others, maintain that despite these vaccine failures, protective 
antibodies will be a necessary component of an effective vaccine. One of the 
best characterized initially identified broadly neutralizing antibodies, b12, 
recognizes the CD4 binding site of gp120, and is able to neutralize forty percent 
of HIV strains in vitro [38]. Passive transfer of physiological doses of b12 
provided sterilizing protection to macaques that were repeatedly challenged with 
virus; one animal remained uninfected after over 40 virus challenges [39]. This 
study supports the notion that humoral immunity can provide protection against 
HIV. Additionally, antibodies provide diverse functions that go beyond virus 
neutralization. ADCC killing by monocytes and NK cells seems to be a potent 
factor in anti-HIV responses [40, 41]. Even IgM and IgA in the mucosa can 
aggregate virions to prevent transversion through mucosal barriers [42]. As the 
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majority of HIV infections are caused by only a single founder virus [43], a 
vaccine that can promote circulating antibody capable of viral inhibition through 
multiple mechanisms has a chance to succeed. 
 
Antibody recognition of HIV gp120 
A major impediment to vaccine development is that we do not yet know 
the parameters that lead to a successful HIV antibody response. HIV-infected 
individuals develop high titers of antibody to the envelope glycoprotein gp120 in 
the primary antibody response, but most often these antibodies are non-
neutralizing [44]. Highly immunogenic variable loops or epitopes found on 
structurally unsound envelope fragments dominate the antibody response [45-
47]. About 2-4% of HIV-infected individuals harbor broadly neutralizing 
antibodies, which are only found months to years after initial infection [48].  
One factor contributing to the lack of a protective response is that the most 
immunogenic portion of gp120 is the variable loop region. Antibodies binding the 
variable region put selective pressure on the virus to mutate gp120 epitopes, 
leading to escape of recognition [49, 50]. As a result, potentially protective 
antibody responses are unable to outpace the mutations created by the low-
fidelity viral polymerase [44, 51-53]. Moreover, some protective epitopes, such as 
the CD4 binding site of gp120, are not easily accessible on the free virus, in part 
due to masking of protein epitopes by carbohydrates [54]. This glycosylation is 
host-derived [55], potentially inducing tolerance in B cells that cross-react with 
self-antigens [56]. In addition, naïve B cells with low-affinity antigen receptors 
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specific for gp120 may not efficiently be triggered by HIV as a consequence of 
the low surface density of gp120 on HIV virions. While influenza, a comparatively 
sized virus, has over 400 spikes [57], HIV averages 10-14 [58, 59]. From tip-to-
tip, the antigen-binding complimentary determining heavy region 3 (CDRH3) 
regions of IgG molecules can span approximately 15 nanometers, far less than 
the distance from spike-to-spike on the surface of HIV (Fig 1.4) [60]. One theory 
is that polyreactivity and subsequent heteroligation of antibody may be beneficial 
for HIV neutralization [59, 61]. This second antigen may be a self-antigen on the 
surface of an infected cell or an HIV virion.  
 
 
Figure 1.4: The low density of envelope spikes on the surface of HIV may 
necessitate heteroligation for B cell activation.  
HIV has an average of 10-14 spikes on the surface of the virion. Inter-spike 
distances are therefore often greater than the span of an antibody. B cell antigen 
receptor crosslinking and B cell activation may therefore require binding to a 
second antigen. Adapted from Pluckthun 2010 [62]. 
 
 
Antibodies that are able to broadly neutralize diverse strains of HIV have 
been isolated, but are rare. A handful of antibodies, such as b12 and 2G12, have 
been studied for decades in an attempt to gain structural insight into antibody-
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gp120 interactions [63]. New techniques in isolating potent anti-HIV antibodies 
from patients has revitalized the broadly neutralizing antibody field [64-68]. These 
broadly neutralizing antibodies are typically highly mutated and are often 
polyreactive [63]. Although many epitopes on gp120 have been shown to be 
targets of broadly neutralizing antibodies, recent studies of HIV-infected sera that 
demonstrate HIV broadly neutralizing activity have shown that a major 
neutralizing epitope is directed against the CD4 binding site of gp120 [69-73]. 
The CD4 binding site is a crucial component of viral attachment and entry into 
the target cell and is one of the most conserved regions of gp120 [74]. 
The recently-isolated broadly neutralizing antibody VRC01 and related 
broadly neutralizing antibodies are the first to surpass the neutralization breadth 
of b12, with the ability to neutralize up to ninety percent of different HIV strains in 
vitro [67, 68]. Despite that these broadly neutralizing antibodies were isolated 
from different individuals, this set of broadly neutralizing antibodies selectively 
use the IGHV1-2*02 gene segment to encode the Ig heavy chain. Structural 
studies have further shown that the complimentary determining heavy region 2 
(CDRH2) of IGHV1-2*02 that encodes VRC01 confers broad neutralization by 
binding the most vulnerable and conserved portion of the CD4 binding site on 
gp120 [75]. The CDRH2 of VRC01 and related antibodies is considerably 
mutated from the germline. Since these neutralizing antibodies were isolated 
from peripheral blood memory B cells of chronically infected patients, the events 
leading to the generation of these antibodies from their germline configuration on 
naïve B cells are unknown. Recent additional studies report broadly neutralizing 
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antibodies from other HIV-infected individuals that also use IGHV1-2*02 in 
conjunction with different light chains [76], highlighting the importance of the 
IGHV1-2*02-encoded Ig heavy chain in neutralization. These findings suggest 
that promoting HIV neutralization by targeting B cells bearing this IGHV segment 
may provide a promising vaccine strategy.  
 
B cells are a heterogeneous lymphocyte population 
A successful HIV vaccine must be able to promote neutralizing antibody 
responses over the dominant non-protective ones. To accomplish this, it may be 
necessary to specifically enlist the participation of different subsets of B cells. 
The antibody response to physiological pathogens is a cooperative effort 
between different B cell subpopulations [77, 78]. The major B cell population in 
mice and humans are CD21+CD23+ follicular (FO) and IgD+CD27– naïve B cells, 
respectively, which require cognate T cell help when responding to protein 
antigens to produce class-switched, affinity-matured antibodies and memory B 
cells, a process that takes time to develop. Additionally, early after infection 
marginal zone (MZ) B cells mount rapid antibody responses to repetitive epitopes 
displayed by pathogens and are not necessarily dependent on T cell help.  
The exact signals that dictate development of immature B cells into FO or 
MZ B cells are unknown. B cell antigen receptor (BCR) signaling is involved, as 
shown by the subset skewing in mice with altered BCR signaling components 
[79, 80]. Fixed specificities in Ig transgenic mice can lead to an increased MZ B 
cell population, indicating that repertoire also influences these cell fate decisions 
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[80-82]. MZ B cells show an increased incidence of receptor editing [83, 84] and 
shorter CDRH3, due to diminished Tdt activity [85]. The MZ B cell pool is also 
hypothesized to be enriched for slightly autoreactive clones [81]. 
MZ B cells reside in the border of the white and red pulp, positioning them 
to be one of the first lines of defense against blood-borne pathogens. MZ B cells 
migrate into the B cell follicles following immunization or TLR stimulation [86, 87], 
and are believed to routinely shuttle antigen into the follicle [88]. Phenotypically, 
MZ B cells express high levels of CD21 and CD1d, allowing them to bind 
complement readily and present antigen to NKT cells [89]. MZ B cells exhibit 
increased expression of co-stimulatory receptors compared to naïve or FO B 
cells, including CD21 and a wider range of TLRs [87, 90, 91]. Human and rodent 
MZ B cells also respond more robustly to T cell-like help or TLR stimulation in 
vitro as compared to naïve and FO B cells [87, 92-97]. As such, MZ B cells 
“deserve special consideration because of their potential as targets for regulatory 
and effector manipulations” [79]. 
It is widely held that MZ B cells do not participate in germinal center 
reactions and thus do not somatically mutate Ig genes, although independent 
studies have directly shown the ability of mouse MZ B cells to induce germinal 
centers and undergo somatic hypermutation [98, 99]. Furthermore, the human 
antibody response to the capsular polysaccharide of both Streptococcus 
pneumoniae and Hemophilus influenzae are dominated by IgM+IgD+CD27+ MZ-
like human B cells [100-102] and are often found mutated [103-109], indicating 
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that MZ B cells are able to undergo somatic hypermutation when responding to 
bona fide pathogens.  
Qualitatively, antibodies from MZ B cells are more often polyreactive than 
antibodies from FO B cells [81]. This polyreactivity may be particularly beneficial 
for protecting against HIV, which has an extremely low surface envelope spike 
density. To cross-link surface BCR, binding to multiple antigens may be 
necessary to activate an HIV-specific B cell [59, 61]. The second antigen is likely 
to be host derived, either incorporated into a virion or on the surface of an 
infected cell. Thus, the rarity of B cells that produce broadly neutralizing 
antibodies may be in part due to peripheral tolerance mechanisms that would 
impede the activation and differentiation of polyreactive B cells during the 
immune response to HIV [110].  
 
Purpose of this study 
 The antibody response to HIV gp120 has been studied for decades, 
largely through analysis of serological data from chronically infected subjects. 
Thus, we set out to investigate the extent to which B cell subsets are capable of 
participating in the primary HIV antibody response to not only better understand 
why this response is typically non-protective but also to inform directions for 
vaccine design. As the primary anti-gp120 response is generally non-protective, 
a carefully designed vaccine may be able to encourage beneficial non-
responsive B cells to participate in an immune response and generate long lived 







MATERIALS AND METHODS 
 
Mice and human samples 
C57BL/6 mice were bred and housed in the Biological Resource Center at 
National Jewish Health or purchased from Jackson Laboratories (Bar Harbor, 
ME). Mice used for antigen-specific flow cytometry controls were as follows: Ig3-
83/3-83Rag1-/- BALB/c mice [111] were a gift from J. Hagman (National Jewish 
Health); HKI65/Vκ10 mice [112] were a gift from L. Wysocki (National Jewish 
Health); VH281 mice [113] and MD4 Ig [114] transgenic mice were gifts from 
J.Cambier (National Jewish Health). Mice used for adoptive cell transfer hosts 
were as follows: BALB/c-Rag2-/-IL2rγ-/- mice (gift of R. Pelanda; [115]) or 
B6.129S7-Rag1tm1Mom/J mice (gift of P. Mararck; [116]). All mice were used 
between 8 and 12 weeks of age and in accordance with the Institutional Animal 
Care and Use Committee at National Jewish Health. Human peripheral blood 
mononuclear cells were obtained in accord with National Jewish IRB protocols. 
Human spleen was obtained with informed consent from non-diseased (healthy) 
individuals as uninvolved tissue being removed at the time of surgery for benign 
or pre-cancerous conditions of the pancreas and in accord with University of 
Colorado IRB protocols and through a collaboration with Dr. Martin McCarter 
(Department of Surgery).  
15 
 
Production of gp120 
gp120 transfection 
COS7 cells (ATCC) were thawed and cultured for at least 5 passages 
before transfection. Cells were transiently transfected with 5 µg of HIV ADA 
gp120 plasmid [117] (provided by TM Ross, University of Pittsburgh) and 30 µL 
Lipofectamine (Invitrogen) in iDMEM (Mediatech) when they were 70-80% 
confluent. Media was exchanged 18 hours later for cDMEM (DMEM (Mediatech) 
+ 10% heat-inactivated FBS (BioSource), 2 mM GlutaMAX-I (GIBCO, Invitrogen), 
100 U/ml Penicillin (GIBCO, Invitrogen), 100 µg/ml Streptomycin (GIBCO, 
Invitrogen)) and supernatant harvested following another 48 hours. Supernatant 
was spun for 10 min at 2,000 g to pellet cell debris and filtered through 0.45 µm 
syringe filters (Millipore).  
gp120 purification  
gp120 was purified by lectin chromatography as described [117]. 
Supernatant was concentrated ~10-fold in 70kD Centricon 100 filters (Millipore) 
and buffer exchanged into PBS. Concentrated supernatant was then rocked 
overnight at 4°C with agarose-bound lectin slurry (Vector Laboratories). The 
bound gp120-lectin was packed into a column and washed with 50 mL PBS. 10 
mL elution buffer (0.5 M Methyl α-D-Mannopyranoside (Sigma) in PBS) was 
loaded onto the column for 1 hr at 4°C. The elution buffer was then passed over 
the column and an additional 5 mL added. The first 20 mL were collected off the 
column as eluate and concentrated and buffer exchanged into PBS and 0.1% 
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azide in a 30 kD filter (Millipore). The lectin was washed with 50 mL of PBS and 
stored in PBS/0.02% NaN3.  
gp120 quality control 
gp120 production was confirmed by western blot and ELISA (as described 
below). Briefly, the western blot was performed by running concentrated eluate in 
a 7.5% acrylamide gel. Proteins were transferred onto PVDF membrane using 
semi-dry electrophoretic transfer at 150 mAMP for 90 min. The membrane was 
then blocked with Odyssey blocking buffer (LI-COR Biosciences) for 1 hr at RT 
and incubated with 1 µg/mL mouse anti-gp120 (ImmunoDiagnostics #1121) in 
PBS/3% FBS rocking overnight at 4°C. The membrane was washed five times 
with PBS/0.1% Tween and 1 µg/mL anti-mouse IgG-680 (BioRad) was used as a 
secondary antibody. The membrane was washed five more times in PBS/0.1% 
Tween (Sigma) and once with PBS and then read on an Odyssey Infrared 
Imaging System (LI-COR Biosciences). 
gp120 immunizations  
10 µg p120 was suspended in sterile PBS and mixed 1:1 in Alu-gel-S 
(“alum”; Serva) for >4 hours at 4°C. Mice were immunized i.p. with 100-200 µL. 
 
Viral-like particles (VLPs) 
VLPs were produced by transient transfection of COS7 cells as described 
above for gp120. Supernatant was purified by ultracentrifugation through a 
glycerol cushion. Briefly, 3 mL of anhydrous glycerol (JT Baker) was underlaid 30 
mL of VLP supernatant in 25x80 mm Ultra-Clear centrifuge tubes (Beckman 
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Coulter) and spun for 2 hr at 100,000 g. Supernatant and glycerol was then 
gently aspirated and the VLP pellet was washed with PBS and resuspended in 
500 µL PBS and frozen at -20°C until use. For VLP immunizations, 30 µL of 
VLPs were suspended in sterile PBS and mixed 1:1 in alum for >4 hours at 4°C 
and mice were immunized i.p. with 100 µL. For VLP sandwich ELISAs, plates 
were coated at 2 µg/mL polyclonal sheep anti-gp120 (Aalto #D7324). Sample 
was detected with human anti-gp41 4E10 which was obtained through the AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.  
 
Dynamic light scattering (DLS) 
VLP supernatant or glycerol-purified VLP products were diluted 1:5 in PBS 
and 100 µL of solution loaded into a microcuvette (Starna Cells). Dynamic light 
scattering was then performed and intensity and size distribution of particles 
determined with a Zetasizer Nano (Malvern Instruments) based on an 
autocorrelation function of scattered light from random Brownian motion of 
particles. DLS was performed with the aid of Dr. Wei Qi, Department of 
Pharmacology, University of Colorado. 
 
Electron microscopy (EM) 
Glycerol-purified products from VLP or “blank” transfected cells were 
applied to formvar-coated grids and stained with 2% uranyl acetate. Electron 
microscopy was performed by Dorothy Dill, Electron Microscopy Center, 
University of Colorado. 
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Enzyme linked immunosorbant assays (ELISAs) 
For the gp120 ELISAs, gp120 was coated on 96 well Maxisorp plates 
(Nunc) at a concentration of 2 µg/mL for 90 min at 37°C and then blocked with 
1% bovine serum albumin (Fisher Scientific) overnight at 4°C. Supernatant or 
diluted serum was added for 90 min at 37°C and then antibodies detected with 
anti-mouse IgG-AP or anti-mouse IgM-AP (Southern Biotech) for 60 min at 37°C. 
gp120-reactive IgM was quantitated with a gp120-specific IgM hybridoma 
developed in-house. ELISAs were developed with 1 mg/mL phosphatase 
substrate (Sigma) diluted in 1 M diethanolamine, 8.4 mM MgCl2, and 0.02% 
NaN3,and read at the 405-nm wavelength. 
 
ELIspots 
 Antigen-specific antibody-secreting cells (ASCs) were measured in 96-
well flat bottom EIA/RIA high-binding plates (Costar, Corning) coated overnight at 
4°C with 2 µg/mL NIP15–BSA or gp120 diluted in 0.05 M K2HPO4 (pH 8.0). Total 
ASCs were measured by coating with 2 µg/mL anti-mouse IgM. Plates were 
washed three times with PBS prior to blocking with warm PBS/1% gelatin 
(Sigma) at 37°C for a minimum of 1 hr. Plates were washed again three times 
with PBS prior to incubation with cells. Cells were seeded in duplicate at 4-6 × 
106 total viable cells per 100 µl in the first well, and two-fold serial dilutions were 
carried out down the plate. Plates were incubated at 37°C in 5% CO2 for 5-6 hrs 
in RPMI Medium (Cellgro) supplemented with 10% heat-inactivated FBS 
(BioSource), 2 mM GlutaMAX-I (GIBCO, Invitrogen), 100 U/ml Penicillin (GIBCO, 
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Invitrogen), 100 µg/ml Streptomycin (GIBCO, Invitrogen), and 0.05 mM 2-
mercaptoethanol (Sigma). Following culture, cells were then lysed with 
H20/0.05% Tween for 10 min at RT and subsequently washed three times with 
PBS/0.1% Tween. Secreted antibody was detected by incubating plates with an 
AP-conjugated goat anti-mouse IgM (Southern Biotech) diluted in PBS/1% 
gelatin for 1 hr at 37°C. After three washes with PBS/0.1% Tween, plates were 
developed overnight at 4°C with 1 mg/ml 5-Bromo-4-chloro-3-indolyl phosphate 
p-toluidine (BCIP; Sigma-Aldrich) salt substrate diluted in an alkaline buffer 
composed of 0.1 M 2-amino-2-methyl-1-propanol, 0.01% NaN3, 0.5 mM MgCl2, 
0.007% Triton X-405, pH 10.25. Plates were washed three times with deionized 
H2O, allowed to dry in the dark at room temperature, and scanned (Epson 
Perfection 2450 Photo Scanner). Developed spots were counted visually from 
the scanned images and the frequency of ASCs per total number of cells plated 
was calculated.  
 
Flow cytometry 
Murine antigen-specific B cell staining and enrichment  
NP7BSA-biotin was purchased from Biosearch Technologies. In-house 
conjugated antigens, NP36CGG (Biosearch Technologies) and gp120 were 
labeled with biotin and Alexa-647 using EZ-link Biotin (Thermo Scientific) and an 
Alexa-647 Microscale Labeling Kit (Thermo Scientific). Splenocytes were 
incubated with antigen for 15 min at 4°C. After washing, anti-biotin beads 
(Miltenyi) were applied to the splenocytes and they were run over an LS 
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magnetic column (Miltenyi), at which point the column-bound and flow through 
fractions were collected and stained. Cells were stained with different 
combinations of anti-CD21, CD1d, B220, CD3 and CD11c and analyzed on a BD 
Bioscience CyAn flow cytometer using FlowJo software (Tree Star). 
Human antigen-specific B cell staining and enrichment  
Human splenocytes were enriched for gp120 binding as described above. 
Cells were then stained with CD3 eFluor 450 (eBioscience), CD20 PerCp 
(Biolegend), CD27 FITC (BD Bioscience), and IgD PE (BD Bioscience).  
Intracellular staining 
To analyze mouse plasma cells, staining was performed by staining 
extracellular targets (B220 and CD138) and then fixing for 20 minutes with 2% 
formaldehyde (Merck) in PBS. After washing twice with PBS, cells were 
permeabilized with freshly made 0.5% saponin (Sigma) in PBS with 0.5% BSA + 
0.02% NaN3. Plasma cells were stained intracellularly with gp120-647, anti-IgM 
PECy-7 (eBioscience, clone Il/41) and anti-Igκ FITC (Southern Biotech, clone 
H139-53.1).  
FACS cell sorting 
 Mouse cell sorting was performed on CD43-depleted splenocytes with 
CD21 FITC and CD1d PE on a Beckman Coulter MoFlo XDP cell sorter to > 95% 
purity. Human cell sorting was performed with CD3 eFluor 450, CD19 FITC 
(eBioscience) CD27 APC (eBioscience), and IgD PE on a Beckman Coulter 





Spleens were flash-frozen with dry ice in O.C.T. (Tissue-Tek) and stored 
at -80°C until sectioning. 7 µm sections were cut on the Cryostat (Leica) onto 
glass slides and dehydrated overnight. Sections were then rehydrated with PBS 
for 20 min and blocked with 2% BSA/0.1% 24G2/0.05% Tween in PBS for 1 hr. 
Fluorescently tagged FITC, Cy3 and Cy5 antibodies in 2% BSA were applied to 
sections for 1 hr and then slides were washed three times shaking in PBS. 
Coverslips were mounted with Fluoromount G (Southern Biotechnologies) and 
sealed with nail polish. Sections were then visualized with a Marianis microscope 
(Zeiss) and analyzed with SlideBook software (3i). 
Indirect fluorescent microscopy  
COS7 cells were grown on microscope chambers and transfected with 5 µg VLP 
plasmid [36] in Lipofectamine. Media was replaced 24 hours later with cDMEM. 
48 hours later the cells were washed twice with PBS and fixed with 4% 
formaldehyde (Merck) for 10 min at RT. Cells were permeabilized with 0.1% 
Triton/1% BSA in PBS for 10 min at RT. Cells were then washed twice with PBS 
and blocked for 30 min RT with 1% BSA. Primary mouse anti-SV40 (Fisher 
Scientific, MAB986MI) or mouse anti-gp120 (ImmunoDiagnostics, #1121) were 
used 1:100 in permeabilization buffer for 1 hr at RT. Cells were then washed 
twice with PBS and anti-mouse IgG-FITC (Zymed) and DAPI (Invitrogen) was 
applied. Cells were washed with PBS and visualized with a Marianis microscope 




For naïve hybridomas, follicular (FO) and marginal zone (MZ) B cells were 
purified from spleens of 4-8 naïve mice in 5 independent sorts and stimulated for 
3 days with 50 µg/mL LPS (Sigma). For VLP-immunized hybridomas, 
splenocytes were harvested at various time points following VLP immunization. 
Splenocytes were fused to SP/2 fusion partners with polyethylene glycol (ATCC) 
for 4 hours. Cells were then serially diluted into flat bottom 96-well culture plates 
(Cellstar) and allowed to grow for 48 hours before addition of selection media 
(complete RPMI with 35.2 µg/mL hypoxanthine (Sigma) and 1.25 µg/mL 
azaserine (Sigma)). Surviving cells were allowed to grow for 7-10 days before 
supernatant was tested for gp120-reactivity by ELISA. Hybridomas were 
considered gp120-reactive if they had a 405-nm OD over 2.0 after successive 
screening and subcloning. Reactivity against the blocking reagent was excluded 
by blocking with bovine serum albumin (Fisher Scientific) in parallel with fish skin 
gelatin (Sigma). Hybridomas that bound gp120, regardless of blocking reagent, 
were considered gp120-reactive. Approximately 2500 and 1700 hybridomas were 
derived from FO and MZ B  cells, respectively, and screened for gp120 reactivity. 
For antigen unselected controls, FO and MZ B cells were sorted from naïve mice 
and stimulated for 3 days with LPS as they were for the hybridoma fusions. RNA 
and cDNA was then made from the bulk population and random heavy chains 






mRNA was isolated from hybridomas with TRIzol (Invitrogen). cDNA was 
synthesized with the SuperScript III synthesis kit for RT-PCR (Invitrogen). PCR 
was performed with High Fidelity Taq polymerase (Invitrogen) with primers 
specifically designed to amplify most murine VDJH or VJk rearrangements [118]. 
PCR reactions were gel purified and products extracted (Qiagen). PCR products 
were amplified by TOPO cloning (Invitrogen) and sequenced (Beckman Coulter 
Genomics). Gene segments were identified using the IMGT database [119]. 
 
Neutralization assays 
HIV pseudovirus constructs were a gift of P. Clapham at the University of 
Massachusetts. Pseudovirus was prepared by co-transfecting JRFL subtype B 
envelope and pNL4.3∆env backbone into 293T cells. Pseudovirus was then 
harvested and frozen until titration and use. 200 TCID50/mL pseudovirus was 
mixed with different concentrations of antibodies and incubated for 30 min at 
37°C. TZM-bl cells were then added to the pseudovirus/antibody mixture and 
incubated for 48 hrs at 37°C. Infection levels were determined with the Beta-Glo 
assay (Promega) and relative light units were read on a luminometer. Percent 
infection was calculated in relation to values from wells that received no antibody. 
Neutralization assays were performed within a BSL-2 laboratory in collaboration 






ELISA plates were coated with 10 µg/mL of chromatin (prepared from 
bovine thymus, gift of L. Wysocki, National Jewish Health) or cardiolipin (Sigma) 
and ELISAs were performed as described above. The 3-83 [120] and B1-8 [121] 
mouse hybridomas were used as negative controls and diluted serum from an 
autoimmune MRL/lpr mouse was used as a positive control. For HEp-2 reactivity, 
100 µg/mL antibodies were applied to HEp-2 antigen substrate slides (BION 
Enterprises) and incubated in a humidified chamber for 1 hr at RT. Slides were 
washed by shaking in PBS and anti-mouse IgM+IgG-Cy5 (Jackson 
Immunoresearch) was added to the slides and incubated for 1 hr at RT. Slides 
were again washed and then integrated intensity was quantified on an Odyssey 
Infrared Imaging System (LI-COR Biosciences). Samples were normalized to a 
positive control (a mouse hybridoma that is reactive to chromatin) and 
considered positive if they were three standard deviations above the negative 
control, the B1-8 hybridoma. 
 
CD4 binding site epitope mapping 
293F cells were transiently transfected with 293Fectin (Invitrogen) and 30 
µg of plasmid encoding either RSC3 or RSC3∆ ([67], gift of J. Mascola, NIH). 
Five days later supernatant was harvested, filtered through a 0.45 µM filter, and 
concentrated with a 30 kD membrane (Millipore). Proteins were purified with 
HisPur Cobalt Spin Columns (Thermo Scientific). RSC3 or RSC3Δ was coated 
onto ELISA plates at 2 µg/mL and incubated for 2 hrs at 37°C. The plates were 
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then blocked for 1 hr with 1% bovine serum albumin in PBS. Antibodies were 
serially diluted with a starting concentration of 100 µg/mL and incubated 
overnight at 4°C. The positive control, VRC01, was obtained through the AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. 
Bound antibodies were detected with either anti-mouse IgM-AP or anti-human 
IgG-AP (Southern Biotech) diluted in 1% bovine serum albumin for 1 hr at 37°C. 
ELISAs were developed and read as described above. 
 
RT-PCR of Ig transcripts 
IGHV1-53*01, mouse kappa constant region, and IGHV1-2*02 primers 
were designed using NCBI Primer-BLAST or IDT SciTools. Murine IGHV1-53*01 
was amplified with 5’AGCCTGGGACTGAACTGG-3’ and 
5’GGTGAAGGTGTAGCCAGAAG-3’. Validity of the product was determined by 
sequencing. Human IGHV1-2*02 was amplified with 
5’AGTGGATGGGATGGATCAAC-3’ and 5’ACCCTGCCCTGAAACTTCT-3’ and 
5’CCTAACAGTGGTGGCACAAACTATGCA-3’ labeled with FAM/Iowa Black (IDT 
DNA). Mouse HPRT and human IgM and GAPDH primers were purchased from 
Applied Biosystems. Template cDNA was diluted in triplicate into a 25 µL 
reaction with Taqman Universal PCR Mix (ABI) and RT-PCR was performed. 
Mouse transcript levels were normalized to HPRT and human transcript levels 





MZ B cell manipulation treatments 
For FTY720 treatment, mice were injected i.p. with 1 mg/kg FTY720 
(Cayman Chemicals) in saline [122]. Efficacy was confirmed by flow cytometric 
analysis of lymphopenia in peripheral blood. For depletion of MZ B cells, 100 µg 
anti-αL (rat IgG2a clone M17/4, purified in-house) and 100 µg anti-α4 (rat IgG2b 
clone PS/2, purified in-house) were injected i.p. in sterile PBS. MZ B cell 
depletion from the spleen was confirmed by flow cytometry at various time points. 
 
Adoptive transfers 
C57BL/6 memory CD4 T cells were generated by immunizing with 10 µg 
gp120 in alum i.p.14 or 30 days prior to harvest. Splenocytes from immunized 
mice were B cell depleted with B220 beads (Miltenyi) and AutoMacs cell 
separation before sorting CD19-CD8-CD4+ cells to >99% purity on the MoFlo. 
Naïve FO and MZ B cells were isolated from unimmunized C57BL/6 mice as 
described above in FACS cell sorting. 2x105 memory CD4 and 1x106 naïve B 
cells were then transferred into BALB/c-Rag2-/-IL2rγ-/- mice or B6.129S7-
Rag1tm1Mom/J mice. Immediately following cell transfer, host mice were 
immunized with 10 µg gp120 in alum i.p. Spleens and sera were harvested 14 







THE PRE-IMMUNE HIV REPERTOIRE 
Background 
The antibody response to HIV gp120 has been studied for decades, 
largely through analysis of serological data from chronically infected subjects. 
However, the antibody response to physiological pathogens is normally 
comprised of a concerted effort between FO and MZ B cells that make different 
qualitative and quantitative contributions. Thus, we set out to investigate the 
extent to which these B cell subsets are capable of participating in the primary 
HIV antibody response to not only better understand why this response is 
typically non-protective but also to inform directions for vaccine design. 
Considering the close parallel in the development and function of human and 
mouse peripheral B cell subpopulations, we used wild type mice to evaluate the 
pre-exposure B cell repertoire available to respond to an HIV vaccine or infecting 
virions. Specifically, we characterized the naïve gp120-reactive repertoire of the 
major B cell subsets in unchallenged mice. We have also supplemented these 








Analysis of B cells capable of recognizing gp120 
To begin to understand what types of B cells are able to recognize the HIV 
envelope protein gp120, we sought to determine which types of B cells are 
capable of producing gp120-binding antibody upon stimulation. Follicular (FO; 
CD21intCD1dint) and marginal zone (MZ; CD21hiCD1dhi) B cells were sorted from 
naïve wild type mice (Fig 3.1.a). The purified B cells were then polyclonally 
stimulated in vitro with LPS [87] for 5 days and supernatant analyzed for IgM and 
IgG secretion. No IgG was detected in supernatant from naïve B cells (data not 
shown). MZ B cells responded more robustly to LPS stimulation and produced 
approximately 10-fold more IgM than the FO B cells (Fig 3.1.b), as expected due 
to their lower threshold of activation to LPS stimulation [96, 97]. To measure the 
amount of g120-binding Ig, supernatant was compared to a gp120-reactive 
hybridoma generated in other studies. As can be seen in Fig 3.1.b, FO and MZ B 
cells produce relatively similar amounts of gp120-reactive IgM. Given that FO B 
cells are the majority subpopulation, although both B cell subsets are able to 
produce anti-gp120 antibody, gp120-binding antibody is more likely to be derived 
from FO B cells in naïve animals.  
Circulating IgM is one of the first lines of defense for the adaptive immune 
system, but an antigen-specific naïve B cell needs to be activated by crosslinking 





Figure 3.1: FO and MZ B cells produce comparable amounts of gp120-
reactive IgM when polyclonally stimulated in vitro.  
a) Naïve splenic FO (CD21intCD1dint) and MZ B cells (CD21hiCD1dhi) were sorted 
from pooled splenocytes and stimulated with 50 µg/mL LPS for 5 days.              
b) Supernatants were analyzed for total (left) and gp120-reactive (right) IgM 
production by ELISA. n=3 independent experiments, 5-8 mice each. P values are 
derived from Student’s t test. 
 
cytometric assays were developed to analyze the phenotype of B cells that are 
able to recognize gp120 by surface BCR binding. As proof of principle, these flow 
cytometric analyses were initially developed using the hapten 4-hydroxy-3-
nitrophenyl (NP) in C57BL/6 mice. The benefits of this approach are that the NP 
antibody response has been studied for decades [123], reagents are available 
commercially conjugated in a variety of formats, and our laboratory has IghB1-8/B1-
8 mice (hereafter referred to as B1-8 mice). These mice have a prearranged VDJ 
in the physiological Ig locus, which when paired with any IgL λ chain, is able to 
bind NP. As approximately 5% of splenic B cells in B1-8 mice are NP-specific 
[124], these mice in the NP system were essentially used as a positive control for 
antigen binding. Single cell suspensions were prepared from spleens of wild type 
(C57BL/6) or B1-8 mice. Splenocytes were then incubated on ice with labeled 
antigen. Initial experiments used commercially purchased NP7BSA-biotin which 
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was revealed with streptavidin phycoerythrin (SA-PE). The left panels of Fig 3.2.a 
show wild type and B1-8 binding of this commercial reagent, with cells pregated 
as singlet and lymphocytes by forward/sidescatter parameters. As expected, a 
higher frequency of B1-8 B cells than wild type B cells bound the commercial NP 
conjugate.  
To analyze the anti-gp120 response, it was necessary to generate our 
own staining reagent. To ensure that our anti-HIV analyses were accurate, we 
first generated an in-house conjugated form of NP. For flexibility of analyses, we 
decided to double label the antigen with biotin and a fluorochrome so that cells 
could potentially be enriched and analyzed in alternate ways. Specifically, we 
selected Alexa-647 because we wanted a bright fluorochrome to detect low 
affinity naïve B cells and wanted to restrict the possible epitopes on the 
fluorochrome to minimize detection of fluorochrome-specific B cells. In contrast to 
allophycocyanin (APC) which approaches 100 kD in molecular weight, Alexa-647 
is approximately 1.3 kD. Brightness, photostability, and most importantly, small 
size, were our primary reasons for selecting this fluorochrome.  
Commercial NP36CGG was purchased and conjugated with EZ-Link Biotin 
and Alexa-647 per manufacturer’s instructions. As can be seen in the right 
panels of Fig 3.2.a, staining percentages in both wildtype and B1-8 mice are 
similar to the commercial reagents. However, staining in NP+ B cells is not as 
high as what was detected with the commercial reagent. This may be because 
the commercial reagent is biotinylated and revealed with streptavidin, essentially 
increasing the valency of the fluorochrome. The in-house NP binding is detected 
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by Alexa 647 fluorescence, which is directly conjugated to the protein. Another 
alternative is that the apparently high-binding cells with the commercial conjugate 
may in fact be background noise of streptavidin detection or PE-specific binding, 
as these high-binding cells are seen with SA-PE staining in the absence of 
biotinylated antigen incubation (Fig 3.2.b). In both of these conjugates, protein 
(BSA or CGG) is present as well as NP. Although some of the B cells are likely 
recognizing these proteins, we believe that the majority of the binding is NP-
mediated, as evidenced by the increased staining in B1-8 mice. 
 
 
Figure 3.2: NP-binding B cells can be detected by commercially available 
and in-house reagents.  
a) Splenocytes from C57BL/6 (wildtype) or IghB1-8/B1-8 (B1-8) mice were incubated 
with NP7BSA-biotin (left panels; revealed with SA-PE) or NP36CGG-bio-647 (right 
panels; shown as 647 fluorescence). Plots are pre-gated on singlet, lymphocyte-
sized cells. Representative of 3 experiments. b) Splenocytes from wildtype mice 
were stained with SA-PE without biotinylated antigen. Representative of 2 
experiments. 
 
 Of course, although B cells are binding these antigens, B cells have other 
receptors than the BCR. It is possible that the detected binding is from lectins or 
other scavenger receptors on B cells. To determine that the flow cytometric 
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antigen staining of B cells was BCR-specific, different BCR transgenic or knock-
in mice were used as staining controls (Fig 3.3 and 3.4). The left panels show 
staining with NP, while the right panels show staining with gp120 labeled with 
biotin and Alexa 647 in the same manner. 
 The first BCR knock-in mice analyzed were Ig3-83/3-83Rag1-/- BALB/c, 
hereafter referred to as 3-83 mice [111]. These mice have an IgH and Igκ in the 
physiological Ig locus that confer specificity to the MHC class I molecule H-2Kb. 
This BCR is autoreactive in C57BL/6 mice but innocuous in BALB/c mice, which 
are H-2Kd. The phenotype of these mice were confirmed with an anti-idiotype 
antibody, 54.1, that recognizes the IgH/Igκ pair (data not shown). Surprisingly, 
there was a high background for both reagents and a significant portion of B220lo 
B cells that bound both NP and gp120 (Fig 3.3.a, top panels). These cells were 
confirmed to be B cells as they were CD11c-Igκ+IgM+ (data not shown). 
 Although unexpected, it was possible that the 3-83 mice were somehow 
an inappropriate control due to some kind of cross reactivity between H-2Kb and 
our staining reagents. So another knock-in mouse was obtained, the HKI65/Vκ10 
mouse specific for Ars (Fig 3.3.a, bottom panels) [112]. These mice are not on a 
Rag-/- background so there are B cells present lacking the Ars specificity. 
However, the NP and gp120-binding cells seen in the HKI65/Vκ10 mice were 
confoundingly idiotype positive (Figure 3.3.b). The experiments performed with 
both of these mice were conducted two independent times each, also in parallel 






Figure 3.3: Mice with a fixed BCR specificity are still capable of binding a 
multitude of antigens.  
a) Splenocytes from C57BL/6 or B6.C20 (wildtype), Ig3-83/3-83Rag1-/- BALB/c (3-
83), or HKI65/Vκ10 mice were incubated with NP36CGG-bio-647 (left panels) or 
gp120-bio-647 (right panels). Plots are pre-gated on singlet, lymphocyte-sized 
cells. Representative of 2 independent experiments, 2 mice each. b) B220+Ag+ 
HKI65/Vκ10 cells from 3.3.a were assessed for HKI65/Vκ10 expression. 
 
 The first indication that the antigen staining was BCR-dependent was 
seen with VH281 mice [113]. The VH281 mice bear a transgenic IgH chain that is 
capable of conferring low affinity binding for human insulin and a wildtype IgL 
repertoire. As compared to Tg- littermate controls, VH281 mice showed reduced 
staining for both NP and gp120 (Fig 3.4, top panels). MD4 mice have a 
transgenic BCR specific for hen egg lysozyme [114]. Consistent with previous 
reports that MD4 is faithfully specific for HEL [125], these mice showed almost no 
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staining with gp120 (Fig 3.4, bottom panels; NP was not tested). Taken together, 
the staining seen with these BCR and transgenic mice are largely inconsistent, 
but the almost absolute lack of staining observed in the MD4 would indicate that 
at least a large portion of the binding is BCR-dependent. It is possible that our 
belief that antibodies are “specific” underestimates the power of immune antigen 




Figure 3.4: Other BCR specificities abrogate binding to multiple antigens.  
Splenocytes from C57BL/6 or B6.C20 (wildtype), VH281, and MD4 mice were 
incubated with NP36CGG-bio-647 (left panels) or gp120-bio-647 (right panels). 
Plots are pre-gated on singlet, lymphocyte-sized cells. VH281 staining was 
performed once with 2 mice, MD4 staining is representative of 2 independent 
experiments, 2 mice each. 
 
Although ex vivo staining of splenocytes was readily detectable (Fig 3.2), 
we decided to employ magnetic column enrichment to capture the majority of 
antigen-binding cells from naïve animals as demonstrated with antigen-specific T 
cells [126, 127] and B cells [125]. Single cell spleen suspensions of wild type or 
B1-8 mice were incubated with either commercial or in-house labeled NP on ice. 
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Cells were then washed and anti-biotin magnetic beads applied for 30 minutes 
on ice. Cells were once again washed and then run over magnetic LS columns. 
Column-bound and flow through fractions were collected and analyzed (Fig 3.5). 
NP-binding enrichment was achieved with both staining reagents (Fig 3.5, top 
panels), and the columns entirely captured NP-labeled cells as there were no 
antigen-bound cells observed in the flow through fractions (Fig 3.5, bottom 
panels). For all future experiments, antigen binding gates will be set based on the 




Figure 3.5: Magnetic column enrichment can be used to capture all antigen-
binding B cells for further analysis.  
Splenocytes from wildtype and B1-8 mice were incubated with NP7BSA-biotin 
(left panels) or NP36CGG-bio-647(right panels) and enriched by magnetic cell 
sorting using anti-biotin beads. Plots of column-bound and flow through cells pre-
gated on singlet, live cells are shown. The gate for NP binding was set by the 
fluorescence level of negative cells that did not bind the column. Representative 
of 2 experiments. 
 
As mentioned above, we chose to double-label the reagents for flexibility 
of analyses. With the biotin/Alexa 647 double-labeling, cells can be enriched via 
the biotin without affecting the Alexa 647 fluorescence. Alternatively, cells could 
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also be enriched with anti-Alexa 647 beads. Figure 3.6 demonstrates that the 
method of enrichment does not appear to affect detection of NP binding by B 
cells. Plots in the top row are from the column bound fraction, pre-gated on 
singlet and lymphocyte-sized cells. The NP+ gates are set from the flow through 
fraction (see Fig 3.5 for an example). As this column method will be used to infer 
subset phenotypes of antigen-binding cells, it is important that the method of 
enrichment does not preferentially alter column binding of different types of B 
cells. The bottom row shows the phenotype of NP+ cells, which is consistent 
between the two methods of enrichment. As B1-8 mice have a greater frequency 
of MZ B cells than wildtype mice [79], it is not surprising that a relatively higher 
percentage of the NP+ cells are of this phenotype. 
One concern of the antigen-binding flow cytometric analyses is that the B 
cells are recognizing the fluorochrome or some neo-antigen caused by the 
conjugation. To attempt to determine if the B cells were truly recognizing the 
antigen, magnetic column-enriched antigen-positive and antigen-negative B cells 
were sorted from the spleens of naïve mice, polyclonally stimulated with LPS in 
vitro and analyzed for Ig secretion by ELISpot (Fig 3.7 and 3.8).  
NP-binding cells were tested first. The gates for sorting were set 
conservatively, as fluorescence was observed to be decreased following the sort 
(Fig 3.7.a). After 3 days of LPS stimulation, NP+ and NP- B cells were analyzed 
for both total IgM and NP-specific IgM antibody-secreting cells (ASCs) (Fig 
3.7.b). The wells shown for total and NP-specific IgM are different concentrations  
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Figure 3.6: Magnetic column enrichment can be performed with either anti-
biotin or anti-647 beads.  
Splenocytes from wildtype and B1-8 mice were incubated with NP36CGG-bio-647 
and enriched by magnetic cell sorting using anti-biotin beads (left panels) or anti-
647 beads (right panels). Enriched NP-binding naïve B cells were then assessed 
for surface phenotype by CD21 and CD1d expression (bottom panels). 
Representative of 2 experiments. 
 
of cells, which is indicated above the wells. Although both fractions were 
relatively capable of secreting IgM, the NP+ fraction had almost 10-fold the 
number of NP-specific IgM secreting cells (Fig 3.7.b), indicating that NP binding 
by flow cytometry is indicative of true antigen recognition. It is noteworthy, 
however, that not all NP-specific B cells were isolated in this staining strategy, as 
a minority of the B cells in the NP “negative” fraction are able to produce IgM that 
binds NP in this assay. These results demonstrate that some B cells capable of 
secreting antibody that recognizes an antigen may not bind this same antigen in 
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flow cytometric analyses. It is also possible that coating the ELISpot plate may 




Figure 3.7: NP-binding B cells are able to produce anti-NP IgM when 
polyclonally stimulated in vitro.  
a) Pooled splenocytes from 8 C57BL/6 mice were incubated with NP36CGG-bio-
647 and enriched by magnetic cell sorting using anti-biotin beads. NP+ and NP- B 
cells were then FACS sorted to >93% purity and stimulated for 3 days with 100 
µg/mL LPS. b) Stimulated B cells were tested for total IgM and NP-IgM secretion 
by ELISpot. Starting concentration of cells is indicated above the wells. 
 
The same procedure was then applied with sorted gp120-binding B cells 
(Fig 3.8). In addition to sorting gp120+ and gp120- B cells from the magnetic 
column-enriched fraction, total B220+ cells were also sorted from the magnetic 
column fraction to determine what level of enrichment the gp120+ staining was 





     
 
 
Figure 3.8: gp120 binding by flow cytometry enriches for gp120-reactive    
B cells.  
a) Pooled splenocytes from 10 C57BL/6 mice were incubated with gp120-bio-647 
and enriched by magnetic cell sorting using anti-biotin beads. B220+ (black), 
B220+gp120+ (red) and B220+gp120- (blue) cells were then FACS sorted to >96% 
purity and stimulated for 3 days with 50 µg/mL LPS. b) Stimulated B cells were 
tested for total IgM and gp120-IgM secretion by ELIspot. A gp120-reactive 
hybridoma was used to correlate total IgM detection with gp120-IgM detection. 
Starting concentration of cells is indicated above the wells. c) Enumeration of 
total IgM (left) and gp120-specific IgM (right) ASCs. 
 
In an effort to correlate total IgM ASC detection with gp120-IgM ASC 
detection, an anti-gp120 IgM hybridoma developed in house was used in parallel 
with the sorted splenocytes (Fig 3.8.b). Of course, the reagents used to coat the 
plate (polyclonal goat anti-mouse-IgM vs. gp120) as well as the binding (Fc 
portion of the IgM vs. antigen-binding regions of purportedly germline IgM) will 
lead to a difference in sensitivity of spot detection. The spots detected using this 
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hybridoma show that as may be expected, the detection of total IgM is more 
sensitive than the gp120-binding IgM. However, although this detection is not 
correlated on a 1:1 basis, the hybridoma spots appear to only be off by a factor of 
~4, while the splenocyte spots are off by a factor of >200. These results would 
that there are a large proportion of gp120 “positive” cells that are false positives. 
We had hoped to sort gp120-binding cells and sequence their IGHV segments 
during different points of the immune response as an alternative to generating 
hybridomas, but that goal does not appear feasible given the high proportion of 
false positives. Other groups have reported similar issues with antigen-specific B 
cell sorting, with only 10% of the resulting antibodies capable of recognizing the 
antigen used to sort the cells [128]. 
As shown in Fig 3.8.c, all three sorted fractions produce comparable 
amounts of IgM when stimulated with LPS. The gp120+ fraction does in fact 
enrich for gp120 IgM-secreting ASCs, and almost no anti-gp120 IgM-secreting 
ASCs were detected in the gp120- fraction. This would indicate that the antigen 
staining by flow cytometry does encompass the majority of gp120-reactive B 
cells. 
 With the gp120 reagent and protocols in place, we then turned to 
examining the phenotype of gp120-binding B cells in wild type mice. Magnetic 
column enrichment was performed as described previously and the phenotype of 
B220+gp120+ B cells was further assessed by CD21 and CD1d expression to 
identify FO (CD21intCD1dint) and MZ (CD21hiCD1dhi) B cells (Fig 3.9.a). The 
results from these experiments show that in an unchallenged wild type mouse, 
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50-60% of splenic B cells that bind to gp120 are FO B cells, whereas only 10-
20% are MZ B cells (Fig 3.9.b). This would suggest that the majority of B cells 
capable of recognizing gp120 in vivo would be FO B cells. 
 
 
Figure 3.9: The majority of gp120-binding B cells in a naïve mouse are of 
follicular origin.  
a) Splenocytes from naïve mice were stained with gp120-bio-647 and enriched 
by magnetic cell sorting using anti-biotin beads. Enriched B220+ gp120-binding 
naïve B cells (left) were then assessed for surface phenotype by CD21 and 
CD1d expression (right). Representative plots of column-bound cells pre-gated 
on singlet, live, B220+ cells are shown. The gate for gp120 binding was set by the 
fluorescence level of negative cells that did not bind the column. b) The percent 
of gp120-binding FO (open circles) and MZ (filled circles) B cells from individual 
mice are depicted. n=3 independent experiments, 2 mice each. P values are 
derived from Student’s t test.  
 
Repertoire analysis of gp120-reactive B cells in naïve mice 
To analyze the naïve anti-gp120 repertoire, hybridomas were generated 
from naïve FO and MZ B cells isolated from wild type mice and screened for 
gp120 reactivity by ELISA. Since these hybridomas were generated from naïve 
mice that had never been exposed to gp120, the antibodies they produced were 
anticipated to be germline-encoded IgM. As a first line of defense for humoral 
immunity, germline IgM is inherently polyreactive and, accordingly, Ig from naïve 
B cells is often capable of binding multiple antigens [129, 130]. Therefore, it was 
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important in the ELISA screening to ensure that the IgM was bound to the gp120 
coated on the plate, and not the protein used for blocking. An anti-gp120 
hybridoma developed from a gp120-immunized mouse was used as a positive 
control. This hybridoma produces IgG and recognizes gp120 regardless of 
blocking reagent, not the blocking reagents themselves (Fig 3.10.a). 
Unfortunately, many of the IgM hybridomas generated from unchallenged mice 
demonstrated varying levels of binding to blocking reagents (data not shown), 
making this straightforward negative control difficult. Instead, hybridomas 
screened for gp120 reactivity by ELISA were considered positive only if the IgM 
bound gp120 regardless of the blocking reagent used. Three examples of the 
types of binding are shown in Fig 3.10.b. The hybridoma in the panel on the left 
is clearly able to recognize gp120 regardless if the ELISA was blocked with BSA 
or gelatin. The hybridoma in the right panel, however, appears to be recognizing 
the BSA as it does not bind to gp120 when blocked with gelatin. Approximately 
30% of the hybridomas initially identified as gp120-reactive were eliminated from 
the study because they in fact were reactive to the milk used for blocking in the 
ELISA. The panel in the middle shows strong binding with one blocking reagent 
and intermediate binding with the other. This situation was not very common, and 
the hybridomas were considered positive for gp120 reactivity if the OD with both 





Figure 3.10: Hybridomas generated from naïve mice need to be tested for 
reactivity to the blocking reagent.  
a) An IgG hybridoma generated from an immunized mouse is able to recognize 
gp120 regardless of blocking reagent, and does not show any reactivity to the 
blocking reagents themselves. b) As IgM is inherently polyreactive, hybridomas 
generated from naïve mice were considered gp120-reactive if they bound gp120 
regardless of the blocking reagent instead of a direct negative control of coating 
with the blocking reagent. The graph on the left shows a hybridoma that is clearly 
gp120-reactive, the graph in the middle is likely showing some recognition of 
gp120 that may be affected by the type of blocking reagent, and the graph on the 
right shows a hybridoma that is specifically recognizing the blocking reagent and 
not gp120. 
 
Sorted FO and MZ B cells from naïve mice were polyclonally stimulated 
with LPS for 3 days to induce cell cycle necessary for fusion. From more than 
2500 FO and 1700 MZ B cell hybridomas generated in 5 independent fusions, 24 
FO and 16 MZ B cell hybridomas were found to produce antibodies that could 
recognize gp120. The Ig heavy chains were sequenced from these gp120-
reactive hybridomas using degenerate IGHV primers [118] and gene segments 
assigned according to the ImMunoGeneTics (IMGT) database [119](Table 3.1 
and Table 3.2). As expected from IgM hybridomas established from naïve mice, 
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their Ig sequences were not mutated from the germline with the exception of on 
FO B cell antibody. The result from these analyses showed that naive FO and 
MZ gp120-reactive hybridomas used similar distributions of IGHV and IGHD 
families (Fig 3.11). However, compared with FO B cells, the IGHJ2 family was 
overrepresented among MZ B cell gp120-reactive antibodies, due, at least in 
part, to a heavily favored VDJ combination (6/16 antibodies analyzed) in the MZ 
population (Table 3.2) that was found in three of the five fusions. This IGHV, 
IGHV1-53, is of particular interest to us because it shows the highest identity with 
human IGHV1-2*02, a common IGHV segment used in human broadly 






Figure 3.11: Repertoire analysis of gp120-reactive hybridomas generated 
from naïve mice.  
Heavy chain V (left), D (middle) and J (right) gene families used by FO (solid) 

















ID IGHV IGHD IGHJ junction 
F02 1-7 3-1 (3) 3 CARGAYYSNYGFAYW 
3 1-19 1-1 (3) 4 CARTGISYGSSDYAMDYW 
8 1-26 2-3 (2) 2 CARRWLRGYFDYW 
28 1-31 6-1 (2) 2 CARNHYFDYW 
18 1-31 6-2 (3) 4 CARVYLRSMDYW 
5 1-52 1-2 (2) 2 CARLRHFDYW 
4 1-53 - 4 CARGSYAMDYW 
16 1-53 1-2 (2) 4 CARSRLLNYW 
7 1-64 1-1 (1) 2 CARLRTWATGFDYW 
33 1-72 1-1 (1) 4 CARSSMVLYYAMDYW 
35 1-75 1-1 (3) 1 CARAGFYYGSSYAHWYFDVW 
29 1-76 3-3 (3) 2 CARLGWDFDYW 
20 1-81 1-1 (3) 3 CARYYGSSPFAYW 
10 2-2 1-1 (2) 1 CAIQLLLRSRGYFDVW 
21 2-2 4-1 (3) 2 CARNSNWVFDYW 
19 2-5 1-1 (3) 3 CAKSGSNYGGFAYW 
31 2-9 2-1 (3) 4 CARNWVYYGNYVAMDYW 
17* 5-9-1 1-1 (3) 1 CTRDGNYYGSSYGYFDVW 
12 10-1 2-3 (3) 3 CVTDGLGTFAYW 
9 10-3 1-2 (3) 1 CVRDYYGGYFDVW 




Table 3.2: gp120-reactive MZ B cell hybridomas. 
 
Table 3.1 and Table 3.2: Naïve gp120-reactive B cell hybridomas. 
Hybridomas were generated from LPS-stimulated naïve FO and MZ B cells (5 
independent fusions from B cell populations sorted from 4-8 mice each). 
Hybridomas were screened for gp120-reactivity by anti-gp120 ELISA. Reactivity 
against the blocking reagent was excluded by ELISAs being performed with BSA 
in parallel with fish skin gelatin. Only 24 FO and 16 MZ hybridomas showed 
reactivity to gp120 under both conditions and were considered positive. The Ig 
heavy chain of each hybridoma was identified using a PCR strategy that 







The CDRH3 for this recurrent VDJ recombination, CARSRLLNYW, was 
suspiciously coded by the same nucleotides in all six of these MZ hybridomas, 
raising a concern about some form of contamination in these studies. When 
analyzing the thirty nucleotides that compose this CDRH3, only six are coded by 
non-germline encoded segments (Fig 3.12.a). Of these six non-templated 
nucleotides, the three between the V and D can be assigned as P nucleotides, 
which is based off of adjacent templated nucleotides. The Asn at position 8 can 
only be encoded with a starting adenine, so this nucleotide is also discounted. 
This leaves the Leu at position 7, which must start cytosine and then thymine, 
discounting another two nucleotides. However, the third nucleotide in the codon 
may be any of the four, and in all six hybridomas this nucleotide is an adenine. 
The enzymes that orchestrate V(D)J recombination are known to have 
preferences for one nucleotide over another in certain situations, so we tried to 
detect the junction of these segments to determine the frequency of an adenine 
at this position. mRNA was harvested from LPS-stimulated cells to match the 
condition the splenocytes were in when the hybridomas were fused. From this, 
111 IGHV1-53/IGHJ2 sequences were amplified and analyzed, and this IGHD to 
IGHJ junction was never detected (Fig 3.12.b). Given that a C57BL/6 mouse has 
29 IGHD segments, the D segment IGHD1-2 used in that recombination should 
have been detected about 5 times. The lack of detection is a significant variation 
from this expectation (p = 0.012, χ2 test). A less direct, but more simple way, to 
rule out cell contamination was to amplify the light chains of these hybridomas. 
Of these six MZ B hybridomas expressing the same VDJ rearrangement, the IgL 
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chain VJ rearrangement was amplified from four hybridomas. To avoid detection 
of the over-abundant defective Igκ transcript produced by the hybridoma fusion 
partner, the IgL PCR products were first digested with PfMI and remaining 
amplicons were sequenced. These results revealed that each harbored a unique 
light chain (Fig 3.12.c), making us confident that this VDJ recombination was in 
fact a unique event in each cell and not the result of hybridoma contamination. 
The IGHV from this recombination, IGHV1-53, was used in only 2 of the 
24 gp120-reactive hybridomas derived from the FO B cells, while it was used in 8 
of the 16 derived from MZ B cells. As the IGHV1 family is the largest IGHV family 
in the mouse, and the most frequently represented in gp120 binding, we 
analyzed the gene segments from this family individually (Fig 3.13). While gp120-
reactive Ig heavy chains from FO B cells use diverse IGHV1 family members, 
gp120-reactive MZ B cells dominantly use IGHV1-53 (Fig 3.13, bottom). 
Furthermore, IGHV1-53 usage was not obviously overrepresented in the 
unselected and antigen non-specific Ig heavy chain repertoire from either B cell 
population (Fig 3.13). These data indicate that IGHV1-53 is preferentially used by 
MZ B cells to encode antibodies that recognize gp120.   
A caveat of this repertoire analysis is that B cells must be in cycle to fuse 
to create hybridomas. Thus, LPS stimulation was used to generate hybridomas 
from unchallenged mice. It is well documented that MZ B cells respond more 
robustly to LPS [96, 97], and there is an additional possibility that LPS stimulation 
may be more effective on different clonotypes, thereby skewing the repertoire. To 








Figure 3.12: The recurring VDJ recombination is not likely due to 
contamination.  
a) A depiction of the recurring MZ B cell CDRH3. Germline encoded nucleotides 
are in red and junctional diversity nucleotides are in blue. b) mRNA was 
harvested from LPS-stimulated cells and transcribed into cDNA. 111 IGHV1-
53/IGHJ2 sequences were then amplified and analyzed. The lack of detection of 
IGHD1-2 is a significant variation from expected (p = 0.012, χ2 test). c) The IgL 
chains were sequenced from 4 of these 6 hybridomas. To avoid detection of the 
over-abundant Igκ transcript from the fusion partner, a PmfI restriction digest was 
performed on the PCR product. Following this digest three of the hybridoma IgL 






Figure 3.13: Mouse MZ B cells repeatedly use the same IGHV gene to 
encode antibodies that recognize gp120.  
IGHV1 family member usage in gp120-reactive FO (solid; top panel) and MZ 
(hatched; bottom panel) hybridomas and antigen unselected controls (open). 
Antigen unselected controls were generated by sequencing Ig genes from bulk 




      
   
Figure 3.14: IGHV1-53 is enriched in the mouse MZ.  
a) FO (solid) and MZ (hatched) B cells were sorted from 4-6 pooled C57BL/6 
mice. Gene expression of IGHV1-53 and the constant region of the 
immunoglobulin kappa chain (IgκC) were assessed by RT-PCR. One 
representative experiment of two shown. b) IGHV1-53 expression was 
normalized to IgκC to control for different amounts of Ig transcript in the different 




different B cell subsets, FO and MZ B cells were sorted from naïve mice and 
IGHV1-53 expression was analyzed by quantitative RT-PCR. As FO and MZ B 
cells express different amounts of IgM and IgD on their surface, IGHV expression 
was normalized to expression of immunoglobulin kappa chain (IgκC) (Fig 3.14.a). 
These results show that IGHV1-53 is 2-3 fold more commonly expressed by MZ 
B cells compared to FO B cells (Fig 3.14.b).  
Many HIV broadly neutralizing antibodies, including those that use the 
IGHV1-2*02 gene segment, have been shown to display polyreactivity as mature 
and germline antibodies [12, 61, 66, 68]. A set of the MZ IGHV1-53 antibodies 
were thus tested for polyreactivity. First, they were assessed for binding to two 
common autoantigens, chromatin and cardiolipin, by ELISA. Fig 3.15.a shows 
that of the three MZ B cell IGHV1-53-encoded antibodies tested, all displayed 
weak reactivity with both chromatin and cardiolipin, while supernatant from 
irrelevant IgM hybridomas showed no binding. These MZ IGHV1-53 antibodies 
were then tested for reactivity to human epithelial HEp-2 cells, which display a 
myriad of autoantigens. Staining on HEp-2 cells is easily visualized to distinguish 
between antigen binding in the nucleus or cytoplasm. The positive control for this 
assay, an IgM hybridoma developed from an autoimmune mouse strain, is 
specific to chromatin. Fig 3.15.b shows that two of the three IGHV1-53 antibodies 
tested brightly stain HEp-2 cells. These antibodies displayed different staining 
patterns, suggesting that they are recognizing different antigens on the HEp-2 







Figure 3.15: Germline IGHV1-53 antibodies are polyreactive.  
a) The IGHV1-53 MZ antibodies were tested for polyreactivity by binding to 
chromatin and cardiolipin by ELISA or b) HEp-2 cells by indirect 
immunofluorescent staining. Mouse IgM hybridomas specific for NP (B1-8) or H-
2b (3-83) were used as isotype controls. Fluorescence intensity was normalized 
to a positive control that is a mouse IgM hybridoma specific for chromatin. 
 
An important feature of protective HIV antibodies is their ability to 
neutralize virus. Although neutralization can be accomplished by binding several 
epitopes on gp120, VRC01 and related broadly neutralizing antibodies target the 
CD4 binding site. To determine whether the gp120-reactive MZ B cell antibodies 
also recognize the same epitope on gp120, we measured the ability of these 
IGHV1-53 antibodies to recognize RSC3, the CD4 binding site epitope used to 
identify VRC01 [67]. RSC3 is a truncated version of gp120 with immunodominant 
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epitopes eliminated and mutated to focus antibody binding on the CD4 binding 
site. Fig 3.16.a shows that whereas VRC01 binds very well to RSC3, the MZ 
IGHV1-53 antibodies do not. The modest binding by antibody MZ14 is likely not 
due to CD4 binding site recognition, as this antibody also bound the control 
RSC3Δ, which has a single mutation abolishing the CD4 binding site (data not 
shown). 
 
Figure 3.16: Germline IGHV1-53 antibodies do not recognize the same 
epitope as the mutated VRC01 and do not neutralize HIV.  
a) The IGHV1-53 MZ antibodies were tested for CD4 binding site recognition by 
ELISA against RSC3. VRC01 was used as a positive control. b) Neutralization 
ability of IGHV1-53 MZ antibodies was determined by TZM-bl assay. Mouse 
IGHV1-53 antibodies were incubated with JR-FL pseudovirus for 30 min before 
culturing with TZM-bl cells for 48 hrs. Percent infection was calculated in relation 
to values from wells that received no antibody. Human b12 was used as a 
positive control for neutralization and a mouse IgM specific for LPS as an isotype 
control.  
 
Finally, we also tested these IGHV1-53 antibodies for their ability to 
neutralize a JR-FL pseudovirus in a TZM-bl neutralization assay. JR-FL 
pseudovirus was mixed with different concentrations of antibodies and incubated 
for 30 minutes at 37°C. TZM-bl cells were then added to the pseudovirus/ 
antibody mixture and incubated for 48 hours at 37°C. Infection levels were 
determined with the Beta-Glo assay (Promega) and relative light units were read 
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on a luminometer. Percent infection was calculated in relation to values from 
wells that received no antibody. These results show that none of the mouse 
antibodies tested demonstrated in vitro neutralization (Fig 3.16.b). As these MZ B 
cell-derived antibodies are unable to neutralize virus, the germline IGHV1-53 
antibodies do not behave like the heavily mutated VRC01, but are similar to the 
purported VRC01 germline and are not protective against HIV in germline form. 
Analysis of gp120-reactive B cells in healthy (uninfected) humans 
Rodent and human B cell subsets are similar in phenotype, anatomical 
location, and function. Although we believe these experiments conducted in mice 
are reflective of human B cell responses, we had the opportunity to obtain human 
spleen samples from Dr. Martin McCarter at the University of Colorado. These 
samples were uninvolved tissue removed at the time of surgery for benign or pre-
cancerous conditions of the pancreas. Of primary interest to us was confirming 
that FO (“naïve”) B cells were more likely to recognize gp120 than MZ (“MZ-like”) 
B cells in humans. To address this, we used the magnetic column enrichment for 
gp120-binding cells in human spleens. The frequency of gp120-reactivity was 
found to vary between three individuals (Fig 3.17.a, top panels). Similarly, the 
distribution of these gp120-reactive B cells into the IgD+CD27– naïve and 
IgD+CD27+ MZ-like B cell populations was also variable but favored, on average, 
the naïve B cell population (Fig 3.17.a, bottom panels and Fig 3.17.b). As 
individuals had varying frequencies of the splenic B cell populations (16-44% 
naïve and 25-35% MZ-like phenotype), gp120-binding cells were normalized to 
the percentage of unenriched populations for each individual. As can be seen in 
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Fig 3.17.b, gp120 binding enriches for naïve B cells almost two-fold, while gp120 
binding does not appear to select for MZ B cells. This further indicates that the 
gp120 precursor frequency is higher in naïve B cells than in the MZ-like B cell 
population in humans.  
To further investigate the potential origins of the human broadly 
neutralizing antibodies, we assessed the expression of IGHV1-2*02 in naïve 
(IgDhiCD27-) and MZ-like B cells (IgDintCD27+) sorted from a healthy human 
spleen. As kappa and lambda light chain usage varies between individuals [131, 
132], IGHV1-2*02 transcript was normalized to IgM expression (IGHM). IGHM 
transcript is depressed in human MZ-like B cells compared to naïve B cells (Fig 
3.18.a), similar to the previously reported expression of IgM in these subsets 
[133]. Analysis of the splenic naïve and MZ-like B cell populations from a single 
individual revealed that while IGHV1-2*02 is indeed expressed by human MZ-like 
B cells, naïve human B cells comparably express this IGHV gene segment (Fig 
3.18.b). Due to unforeseen complications of sorting frozen human spleen 
samples, we were not able to repeat this experiment. So we resorted to sorting B 
cell subsets from human peripheral blood. Although rodent MZ B cells are sessile 
and restricted to the spleen, humans also have a circulating MZ-like B cell 







blood was collected and subjected to Ficoll purification. As B cells comprise only 
~5% of the circulating mononuclear cells in human blood, the B cells were further 
enriched by a human B cell negative selection kit and naïve (IgDhiCD27-) and 
MZ-like (IgDintCD27+) B cells were FACS sorted to >90% purity. Although it had 
been previously reported, the depressed IGHM expression in MZ-like B cells (Fig 
3.18.a) was slightly counterintuitive because MZ-like B cells have higher IgM 
expression on their surface than naïve B cells. Therefore, for this experiment, we 
also measured Igκ (IGKC) and Igλ (IGLC) expression to see if there was 
something about the detection of IgM or if transcript levels are truly depressed in 
the MZ-like B cells.  
Fig 3.19.a shows individual relative mRNA levels of each sample. One 
individual had very high IGHV1-2*02 expression in their naïve B cell 
compartment (Fig 3.19.a). IGHM was expressed at higher levels in the naïve B 
cells of all 4 individuals, confirming the measurement in the spleen sample in Fig 
3.18. IGKC and IGLC expression was also higher in naïve cells, but overall the 
magnitude of expression was much lower than IGHM so we decided to continue 
normalizing IGHV1-2*02 to IGHM. As can be seen in Fig 3.19.b, the overall 
expression of IGHV1-2*02 is higher in naïve B cells, mostly due to the first 
individual. IGHM is also higher, but is consistent between samples. When 
IGHV1-2*02 is normalized to IGHM, there is approximately 1.8-fold decrease in 






Figure 3.17: gp120 binding appears to enrich for naïve human B cells.  
gp120-binding enrichment as described in Fig 3.9 was performed with three 
human spleen samples. a) Individual dot plots of gp120-binding by column-
enriched CD20+ B cells (top row) and the distribution of these gp120-reactive B 
cells as IgD+CD27– naïve and IgD+CD27+ MZ-like B cells (bottom row) of each 
spleen are shown. b) The percent (top) and normalized frequency (bottom) of 
CD20+ gp120-binding B cells in the naïve (open circles) and MZ-like (filled 
circles) B cell populations are depicted for each individual. Percent of gp120-
reactive naïve and MZ-like B cells were normalized to the frequency of each 





Figure 3.18: IGHV1-2*02 is comparably expressed by both naïve and MZ-
like human B cells in the spleen.  
a) Naïve (solid) and MZ-like (hatched) B cells were sorted from a human spleen. 
Gene expression of IGHV1-2*02 and human IgM (IGHM) were assessed by RT-
PCR. b) IGHV1-2*02 expression by naïve and MZ-like B cells is normalized to 






Figure 3.19: IGHV1-2*02 is comparably expressed by both naïve and MZ-
like human B cells in the blood.  
a) Naïve (open) and MZ-like (solid) B cells were sorted from human PBMC (n=4). 
Gene expression of IGHV1-2*02, IGHM, IGKC, and IGLC were assessed by RT-
PCR. b) Combined expression of IGHV1-2*02 and IGHM. Circles represent 
individual data points, bars represent the mean. c) IGHV1-2*02 expression by 
naïve and MZ-like B cells is normalized to IGHM to control for different amounts 




To better understand which B cell subsets are capable of generating an 
anti-gp120 antibody response, we first analyzed FO and MZ B cell populations 
from naïve mice using a flow cytometric-based system. In order to validate this 
system, we first used conjugated NP. As seen in Fig 3.2, our in-house 
conjugated NP shows similar staining to commercially available NP in both 
wildtype and B1-8 mice. Additionally, this in-house conjugated NP can be used to 
enrich NP-specific B cells (Fig 3.5, 3.6 and 3.7). Intriguingly, the use of different 
BCR transgenic and knock-in mice yielded varying results. For the 3-83 and 
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HKI65/Vκ10 mice, B cells supposedly bearing the fixed BCR were able to bind 
multiple antigens (Fig 3.3). However, the frequency of antigen staining was 
decreased in the fixed heavy chain VH281 mouse and completely abrogated in 
the MD4 mouse (Fig 3.4), suggesting that the binding seen in wildtype mice is in 
fact BCR-mediated.  
Based on frequency and absolute numbers of gp120-reactive B cells, our 
data indicate that the majority of B cells capable of binding gp120 on their 
surface are of follicular origin in both humans and mice (Fig 3.9 and 3.17). FO B 
cells also outnumber MZ B cells in both rodents and humans. If FO B cells 
dominate the primary anti-gp120 response, which is not protective [44, 47], then 
a useful vaccine strategy may involve the promotion of other B cell subsets in an 
HIV response. 
Hybridomas were generated from sorted naïve FO and MZ B cells to 
assess the molecular landscape of gp120 recognition. The MZ B cell hybridomas 
preferentially used IGHV1-53 to recognize gp120 (Table 3.2). However, the 
hybridomas are derived from LPS-stimulated B cells. MZ B cells respond more 
robustly to LPS [96, 97], so the LPS stimulation could have caused differential 
repertoire skewing between the subsets. To address this, we independently 
demonstrated by quantitative RT-PCR that IGHV1-53 is disproportionately 
expressed by naïve MZ B cells (Fig 3.14). The human ortholog of this IGHV 
segment is IGHV1-2*02, which encodes the newly described broadly neutralizing 
antibody VRC01 [67]. B cell subsets from human splenocytes (Fig 3.18) and 
PBMC (Fig 3.19) showed no preferential expression for IGHV1-2*02 in MZ-like B 
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cells as had been detected in mouse MZ B cells (Fig 3.14). The significance of 
IGHV1-2*02-encoded antibodies is discussed in further detail in Chapter V. 
To further examine the quality of the mouse IGHV1-53 MZ antibodies, a 
subset was tested for autoreactivity, specific epitope recognition and 
neutralization capability (Fig 3.15 and 3.16). Although these IGHV1-53 antibodies 
were observed to bind gp120, they also weakly bind chromatin, cardiolipin, and 
HEp-2 cells but are unable to bind the CD4 binding site of gp120 or neutralize 
HIV in vitro. These observations provide further evidence that in order to be 
protective, these B cells would likely need to be drawn into a germinal center 







THE RESPONDING HIV REPERTOIRE 
 
Background 
 To examine the anti-gp120 antibody response with the focus on the roles 
that different B cell subsets play, we first sought to better dissect the 
contributions of FO and MZ B cells. Several limitations are in place for definitive 
study of MZ B cells. Firstly, upon activation and stimulation, they change location 
and phenotype and can no longer be identified as MZ B cells. Secondly, 
obtaining large numbers of these cells for experiments is challenging. Finally, 
when transferred, MZ B cells do not localize to their normal anatomical niche. 
Despite all this, a few tools are at our disposal. The S1P agonist FTY720 causes 
lymphopenia by binding and downregulating S1P1, prohibiting lymphocyte egress 
from lymphoid organs [134]. MZ B cells are sequestered in the marginal zone by 
S1P1 expression, which prevents them from responding to CXCL13 [122]. 
FTY720 treatment and subsequent S1P1 antagonism therefore also induces 
CXCL13-responsiveness and relocalization of MZ B cells into the follicle. MZ B 
cells are also docked in the marginal zone by LFA-1 and α4β1 integrin binding 
[135]. Antibodies are available that bind and the α4 and αL integrin subunits. In 
vivo treatment with these antibodies causes MZ B cells to release into the blood 
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and their eventual depletion [135]. We use these tools to gain a better 
understanding of MZ B cell antibody responses. 
 The overall goal of our study is to understand the potential of pre-immune 
B cells to better direct vaccine efforts. The gp120 monomer has been 
investigated as a candidate vaccine, with mostly disappointing results [12, 17]. 
One potential reason that it was not  protective is that it fails to induce 
neutralizing antibodies. This is likely because gp120 is presented as a trimeric 
spike on the surface of the virus, which would have different epitopes than the 
monomer alone. We obtained constructs for HIV viral-like particles (VLPs) from 
Ted Ross at the University of Pittsburgh [36, 37]. These VLPs, which are 
genomeless and non-replicative, are safe and are expected to recapitulate the 
viral structure. When the viral structural proteins are produced by transient 
transfection in primate cells, they assemble and bud out of the cell as an intact 
virus would. The VLPs are then harvested from the supernatant and used as 
antigens. VLPs are an enticing vaccine platform because it has become clear 
that antigen structure is a crucial component of generating neutralizing antibodies 
to HIV.  
Serology has dominated the study of HIV antibody responses over the 
past few decades. By using a mouse model, we have the opportunity to go 
beyond serology and analyze the frequencies and phenotypes of responding B 
cells at different time points of antigen exposure. To validate the flow cytometric 
protocols we wished to use with VLPs, immunizations were also performed with 
monomeric gp120 in alum as a high control.  
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We also desired a sensitive method to follow a particular clonotype. 
Traditionally, this has been achieved by hybridoma studies or development of an 
anti-idiotype antibody. Hybridoma studies were undertaken, but can be time 
consuming and not entirely robust. While anti-idiotypes are certainly useful, two 
concerns arise. The idiotype is never 100% specific; additionally, mutations 
generated in the immune response could lead to a lack of detection. Deep 
sequencing of IGHV is certainly an appealing option, but not a feasible one at the 
time these studies were conducted. Instead, we attempted to devise our own 
assay using real time polymerase chain reaction (RT-PCR) to measure the 
expression of IGHV segments from a pool of cells in responding mice.  
 
Results 
Dissecting the contributions of different B cell subsets 
One of the difficulties in dissecting antibody responses is that FO and MZ 
B cells change phenotype upon activation and differentiation [136]. Upon antigen 
recognition, MZ B cells leave the MZ to differentiate into short lived plasma cells 
or potentially seed germinal centers in the follicle. With the possibility that MZ B 
cells retain their phenotype for at least a few days before full differentiation, we 
were hoping to evaluate MZ B cell responses early during the primary immune 
response in an intact mouse. FTY720 treatment, which forces MZ B cells into the 
follicle by permitting CXCL13 chemotaxis, was used as a proxy for this migration 
to try to assess how long MZ B cells can be recognized as such during an 
immune response. Mice were either left untreated or given 1 mg/kg FTY720 and 
analyzed 2-5 days later by flow cytometry and immunofluorescent histology (Fig 
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4.1). As can be seen in Fig 4.1.a, MZ B cells are still detectable by flow cytometry 
2 and 3 days following FTY720 administration. CD21 expression is depressed on 
MZ B cells 2 days after FTY720 treatment but CD1d does not appear to be 
affected (Fig 4.1.a, bottom row). No changes in CD21 or CD1d expression were 
observed at days 4 and 5 (data not shown). MZ displacement into the follicle, 
exemplified by a lack of IgMhi (red) cells around the marginal zone, was 
confirmed by immunofluorescent histology (Fig 4.1.b). 
As a single dose of FTY720 treatment was not enough to cause 
phenotypic changes in MZ B cells, we investigated if repeated treatments would 
achieve this effect. Mice were either left untreated or given FTY720 every three 
days and sacrificed at day 7, 10 or 12. As seen in Fig 4.2.a, even repeated 
treatment with FTY720 did not induce phenotypic changes. The decrease in 
CD21 expression seen after 2 days in Fig 4.1 was not observed with repeated 
treatment. Although the MZ B cells were still phenotypically distinguishable, they 
were not in their physiological location (Fig 4.2.b). The most likely reason for 
these results is that mere relocation, in comparison to antigen recognition and 
response, is not enough for MZ B cells to alter their phenotype. In conclusion, MZ 
B cell differentiation needs to be monitored in an antigen response setting.  
If observing MZ B cells in an intact mouse is not feasible, then adoptive 
transfers become necessary to assess the quality of MZ B cell antibody 














Figure 4.1: FTY720 treatment causes relocalization and slight phenotypic 
changes in MZ B cells.  
Mice were either untreated or given 1 mg/kg FTY720 i.p. and sacrificed 2 or 3 
days later. a) Plots are pregated on singlet lymphocyte-sized B220+ cells. 
Phenotype (CD21 and CD1d expression) of FTY720-treated MZ B cells (red) is 
compared to untreated FO (gray) or untreated MZ B cells (black). b) Localization 
of MZ B cells was determined by immunofluorescent histology. Spleen sections 
were stained for MOMA (a marginal zone marker; green), IgD (blue) and IgM 





Figure 4.2: Prolonged FTY720 treatment retains MZ B cells in the follicle but 
does not induce phenotypic changes.  
Mice were either untreated or given 1 mg/kg FTY720 i.p. every 3 days and 
sacrificed at various time points. a) Plots are pregated on singlet lymphocyte-
sized B220+ cells. Phenotype (CD21 and CD1d expression) of FTY720-treated 
MZ B cells (colored lines) is compared to untreated FO (gray) or untreated MZ B 
cells (black). b) Localization of MZ B cells was determined by immunofluorescent 
histology. Spleen sections were stained for MOMA (green), IgD (blue) and IgM 






from a single spleen usually yields approximately 1x106 MZ B cells. Several 
attempts were made to enrich MZ B cells before FACS sorting so that more cells 
would be available for subsequent experiments. Shown in Fig 4.3.a is an ungated 
dot plot of splenocytes from a naïve C57BL/6 mouse. As can be seen in the 
CD21hiCD1dhi gate, MZ B cells comprise approximately 4% of this population and 
FO B cells outnumber MZ B cells by about 10-fold. Unfortunately the markers 
that distinguish FO and MZ B cells, aside from CD23 (which includes immature B 
cells), are not binary. FO B cells are CD21intCD1dintIgMintIgDhi while MZ B cells 
are CD21hiCD1dhiIgMhiIgDlo. We undertook different approaches with Miltenyi 
magnetic cell depletion to enrich for MZ B cells. Firstly, depletion of CD43+ 
splenocytes enriches for naïve B cells by depleting platelets, myeloid cells, T 
cells and NK cells. To further enrich for MZ B cells over FO B cells, depletion of 
CD23+ and IgD+ cells was attempted. 
The top row of plots in Fig 4.3.b shows the cells that bound the column, 
which would be discarded for the hypothetical FACS sort. Interestingly, although 
MZ B cells do not express CD23, this depletion caused a nontrivial portion of MZ 
B cells to bind the column (Fig 4.3.b top row, second and fourth plots). The 
fraction of interest is the flow through fraction, depicted in the bottom row of plots 
in Fig 4.3.b. The combined depletion of CD43/CD23/IgD (fourth plot) actually did 
not vary from the double depletion of CD43/CD23. However, the depletion of 
CD43 also mirrors the double depletion of CD43/IgD, bringing into question the 
effectiveness of the anti-IgD biotin used. Based on the final percentage and total 
numbers (data not shown) of MZ B cells in the flow through fraction, a simple 
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CD43 depletion is the most effective method. It is possible that increasing the 
number of factors of enrichment will cause an increased loss of MZ B cells, which 




Figure 4.3: CD43 depletion is the most effective pretreatment for FACS 
sorting of MZ B cells.  
a) Ungated plot showing the percentages of FO (CD21intCD1dint) and MZ 
(CD21hiCD1dhi) B cells from whole splenocytes. b) Ungated plots of cells from the 
column-bound (top row) or flow through (bottom row) fraction of indicated 
treatments. Representative of 3 experiments. 
 
Another method was employed to specifically isolate MZ B cells. Although 
humans have a circulating MZ-like B cell subset, MZ B cells in rodents are 
restricted to the spleen. We aimed to make MZ B cells the majority population of 
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lymphocytes in the blood and to harvest and FACS sort the peripheral blood 
lymphocytes (PBL) instead of the spleen. Administration of antibodies that block 
α4 and αL integrin subunits dislodge MZ B cells from the marginal zone, 
whereupon they are released into the bloodstream [135]. To harvest the MZ B 
cells from the blood, the anti-integrin antibodies were administered i.v. and mice 
sacrificed 3 hours later [135]. The S1P1 agonist FTY720 causes lymphopenia by 
preventing egress from lymphoid organs [134]. By using both of these therapies 
together, we thought we could harvest the majority of MZ B cells directly from the 
blood, with fewer contaminating cells usually found in spleen sorts. Mice were 
treated with vehicle controls, anti-integrin antibodies, FTY720, or the combination 
of FTY720 and anti-integrin antibodies together and then sacrificed three hours 
later.  
The top row of dot plots in Fig 4.4.a show the lymphocyte populations in 
the peripheral blood of these animals. As compared to control, the anti-integrin 
treated animal has an increase in the frequency of B220+ cells (25% vs. 40%). 
The FTY720 treated animal is already exhibiting lymphopenia, with just 5% 
B220+ cells in the blood. The two double treated animals shown have a high 
percentage of B cells in their blood (33% and 38%), but few T cells (12% and 
5%), indicating that both treatments were effective. To assess the extent of 
release of the MZ B cells, the spleens were also analyzed (Fig. 4.4.a, bottom 
row). The lowest frequency of MZ B cells was seen with anti-integrin treatment 
alone, and the double treatment appeared to prevent the full release of these 
cells. In retrospect, this is not surprising because in addition to lymphopenia, 
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FTY720 treatment causes MZ B cells to migrate into the follicle [122]. If the cells 
are no longer physically located in the marginal zone, the anti-integrin treatment 
is likely to be less effective.  
 
 
Figure 4.4: Collection of MZ B cells from the blood is not feasible.  
Mice were treated with vehicle control (control), 100 µg anti-αL and anti-α4   
(anti-integrin), 1 mg/kg FTY720 (FTY720), or both (anti-integrin and FTY720) and 
sacrificed 3 hours later. Plots are pre-gated on singlet lymphocyte-sized cells.    
a) the peripheral blood and spleen were analyzed for lymphocyte populations.   
b) B cells in the blood were analyzed for CD21 and CD1d expression to detect 
MZ B cells. Representative of 2 experiments. 
 
In analyzing the MZ B cells in the blood, the highest percentage of MZ B 
cells is in the anti-integrin treated mice (Fig 4.4.b). Although there appear to be 
fewer FO B cells in the double-treated mice, the overall percentage of MZ B cells 
(less than 2%) is fairly low. Again, it seems that the FTY720 treatment may 
interfere with the full release of MZ B cells. None of the conditions tested 
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generated enough MZ B cells to merit this approach of isolation. Therefore we 
continued to perform sorts on CD43-depleted splenocytes. 
Our laboratory has previously tried to track MZ B cell responses by 
transferring congenically marked MZ B cells into other hosts. This resulted in MZ 
B cells not localizing properly (data not shown). We hypothesized that the 
inability of transferred cells to home to the marginal zone may be due to host MZ 
B cells occupying the niche, forcing the transferred cells to go elsewhere. We 
sought to improve upon these results by treating the host mice with anti-integrin 
antibodies to “free up” room for the transferred MZ B cells. Initial experiments 
were performed 4 days after anti-integrin treatment and did not improve the 
localization of transferred cells (data not shown). However, the rat anti-integrin 
antibodies are likely still circulating at this time [137].The final experiment was 
conducted 10 days after anti-integrin treatment, when the host MZ B cells are 
starting to return as determined by flow cytometry, suggesting that transferred 
cells might be able to localize to the MZ. 
FACS-sorted B1-8 MZ B cells, which express IgMa, were transferred into 
C57BL/6 IgMb hosts that had received anti-integrin antibodies 10 days prior (Fig 
4.5). To enhance detection of the transferred cells, splenocytes were enriched on 
a magnetic column by anti-B1-8 idiotype staining. Fig 4.5.a shows the control 
mice, which were either unmanipulated or MZ-depleted, but did not receive any 
IgMa cells. Column-bound cells were analyzed for B220 and IgMa expression (Fig 
4.5.a, top plots). B220+IgMa- (yellow gate) and B220+IgMa+ (blue gate) cells were 
then analyzed for CD21 and CD1d expression to determine the subset 
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phenotype of these cells (Fig 4.5.a, bottom plots). Next, six mice received 5x106 
IgMa MZ B cells from B1-8 mice (Fig 4.5.b). As can be seen in the blue gate, 
these mice have an easily detectable population of B220+IgMa+ cells. However, 
when analyzed phenotypically, these IgMa cells are not their original phenotype 
of CD21hiCD1d hi. These spleens were also analyzed by immunofluorescent 
histology (Fig 4.5.c). The unmanipulated mouse has MZ B cells in their proper 
location, shown by the ring of IgMhiIgDlo cells around the IgMintIgDhi FO cells. The 
mice that received anti-integrin treatment do not have B cells in the marginal 
zone, regardless if IgMa+ MZ B cells were transferred. Based on these results, 
the transferred MZ B cells did not maintain their phenotype or localize to the 
marginal zone. It is possible that even 10 days after MZ B cell depletion, there is 
still sufficient circulating anti-integrin antibodies to prevent localization of 
transferred cells to the marginal zone.  
Given this collection of experiments, it does not seem likely that 
transferred MZ B cells will maintain their phenotype in a physiologically intact 
host. As part of their advantage is their location in the marginal zone, which is the 
first encounter for splenocytes with any blood borne pathogen, we will not be 
able to recapitulate this in a transfer system. 
One powerful facet of adaptive immunity is the formation of germinal 
centers, which allow B cells to somatically hypermutate their antigen-binding 






Figure 4.5: Transferred MZ B cells do not maintain their phenotype.  
Host C57BL/6 IgMb mice were treated with anti-integrin antibodies 10 days 
before transfer. 5x106 B1-8 IgMa MZ B cells were transferred i.v. and mice were 
sacrificed 2 days later. To enrich for transferred cells, splenocytes were stained 
with an anti-B1-8 idiotypic biotinylated antibody and anti-biotin beads were 
applied before running over a magnetic column. Plots are from the column-bound 
fraction and are pre-gated on singlet lymphocyte-sized B220+ cells. a) Control 
mice were either unmanipulated (left) or MZ depleted (right). B220+IgMa- (host B 
cells; yellow gate) and B220+IgMa+ (transferred B cells; blue gate) were analyzed 
for CD21 and CD1d expression. b) Representative experimental mice were 
analyzed in the same manner. c) Representative histology of control and 











germinal centers to undergo somatic hypermuation and subsequent affinity 
maturation. Germinal center B cells are class switched, so unlike naïve B cells, 
they no longer express surface IgD. Somatic hypermutation is the basis for 
affinity maturation, and is a desirable outcome of B cell responses to vaccines. 
Two independent laboratories have used adoptive transfers with immune 
deficient or Ig Tg mice to study the antibody response of isolated B cell subsets 
[98, 99]. They found that contrary to dogma, MZ B cells are capable of somatic 
hypermutation.  
We wanted to recapitulate these results using gp120 as an antigen. To 
encourage germinal center formation, primed CD4 T cells were harvested from 
mice immunized with gp120 in alum 14 days prior. To ensure that no memory B 
cells contaminated the transfer, these splenocytes were B220 depleted by 
AutoMacs and then FACS sorted for CD19-CD8-CD4+ cells. FO and MZ B cells 
were also sorted from naïve animals. A preliminary experiment where the cells 
were transferred at a 1:1 ratio showed the T cells preferentially expanded and 
became >30% of the splenocytes at the time of harvest (data not shown), so the 
ratio was skewed towards B cells in this experiment. 1x106 purified B cells and 
2x105 CD4 T cells were transferred i.v. into BALB/c-Rag2-/-IL2Rγ-/- mice. The 
mice were then immunized i.p. with 10 µg gp120 in alum and sacrificed 14 days 
later. One mouse did not get immunized as a control. 
B cells were analyzed as CD3-CD11c- and then identified by Igκ 
expression. B220, which can be expressed on a variety of cell types such as NK 
cells and dendritic cells, did not correlate with Ig staining, and was not used for 
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this analysis. IgD staining was also used to try to identify B cell class-switching. 
Strangely, there was a large population of IgD+Igκ- cells, which we believe are not 
truly B cells (Fig 4.6.a). Naïve IgD+Igκ+ B cells (gray gates) and class-switched 
IgD-Igκ+  B cells (black gates) were then analyzed for PNA binding, a common 
indicator used to identify germinal center B cells [138]. Regardless of antigen 
exposure, all naïve B cells in this system bound PNA. The fact that the naïve B 
cells from the unimmunized mouse bound PNA would indicate that this result is 
not indicative of germinal center formation. The class-switched B cells, however, 
had bimodal PNA binding, indicating that cells in the PNA+ peak may truly be 
participating in germinal center reactions. These results would suggest that 
although PNA-binding is associated with germinal center formation, its use as 
absolute proof in a transfer setting may not be appropriate. 
We were also interested in the anatomical structure of these B cell 
responses. In order to generate high affinity antibodies, B cells need to interact 
with antigen-specific CD4 T cells and follicular dendritic cells (FDCs). When we 
analyzed the spleens by immunofluorescent histology, we discovered that the 
lymphoid architecture was completely disorganized. Everything that was CD19+ 
was also PNA+, and the IgD staining was indiscriminate (Fig 4.6.b, left). One 
possibility was that the staining had gone awry, so we repeated it in parallel with 
sections from an intact C57BL/6 mouse that had been sacrificed 14 days after  
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Figure 4.6: PNA binding by B cells transferred into an immunodeficient 
host may not be indicative of germinal center formation. 
CD4 T cells were FACS sorted to >99% purity from day 14 gp120/alum mice. 
Naïve FO and MZ B cells were FACS sorted to >92% purity. 2x105 CD4 T cells 
and 1x106 FO or MZ B cells were transferred i.v. into BALB/c-Rag2-/-IL2Rγ-/- mice 
which were then immunized with 10 µg gp120 in alum. One mouse was left 
unimmunized as a control. Mice were sacrificed 14 days after transfer and 
immunization. a) Phenotypic analysis of CD11c-CD3- B cells. IgD+Igκ+ naïve 
(gray gate) and IgD-Igκ+ class-switched (black gate) B cells were assessed for 
PNA binding. b) Spleen sections were stained for germinal center formation with 
PNA (green) IgD (blue) and IgM (red). Left is a representative section from this 
experiment; right is a positive control from an NP-CGG-immunized C57BL/6 




immunization with NP-CGG in alum (Fig 4.6.c, right). This spleen appeared 
normal, leading us to conclude that the spleens of the host mice were lacking 
organization. Notably, splenic organization has been shown to be dependent on 
B cell-derived lymphotoxin signaling [139-141]. It is possible that since the 
spleens of the host mice developed without B cells, normal follicles and germinal 
center structures are not able to form upon cell transfer and immunization. 
One reason that T cells may have preferentially expanded in these 
experiments is that the transferred cells were from a C57BL/6 mouse and the 
host mouse was on the BALB/c background, potentially leading to a graft-versus-
host response from the CD4 T cells. For the next experiment we obtained Rag1-/- 
mice on a C57BL/6 background, so the transferred cells should be tolerant of the 
host MHC. Additionally, the primed T cells were harvested at day 30 instead of 
day 14, to ensure that they were truly in the memory phase of their differentiation. 
1x106 purified naïve B cells and 2x105 memory CD4 T cells were transferred i.v. 
and all mice except one were immunized with 10 µg gp120 in alum and sacrificed 
14 days later. B cells were identified as CD3-CD11c- Igκ+ and then analyzed for 
phenotypic markers. Germinal center cells were defined as IgD-PNA+ cells (Fig 
4.7.a, top row). Class switching was also analyzed by IgD and IgG1 (the 
dominant isotype in alum-induced responses) expression (Fig 4.7.a, bottom row). 
While there was some background PNA binding in the IgD- cells of the 
unimmunized mouse, there was no class switching.  
The results of these analyses are summarized in Fig 4.7.b. MZ B cells 
have been reported to upregulate costimulatory molecules to a higher degree 
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than FO B cells upon stimulation [142], so we found it interesting that there 
appeared to be an increased expansion of CD4 cells in the mice that received 
MZ B cells, as this may indicate more effective activation of these cells. The 
frequency of B cells with a germinal center phenotype seemed comparable 
between the two groups, but MZ B cells appeared more likely to class switch to 
IgG1 than FO B cells. 
The sera of these mice were also analyzed for antibody production (Fig 
4.7.c). All mice produced IgM, regardless of immunization. The mice that 
received MZ B cells produced more IgM than mice that received FO B cells. 
Additionally, MZ B cells generated slightly more IgG. The mouse that was not 
immunized produced very little IgG, indicating that the IgG from immunized mice 
was generated in a true immune response. However, when gp120-specific IgG 
was analyzed, only two out of the eight mice had detectable levels. Had the 
antigen-specific response been stronger, we would have gone on to evaluate 
several components at the molecular level, such as measuring AID expression or 
sequencing IGHV segments and determining mutation rates. When these 
spleens were analyzed by immunofluorescent histology, they were disorganized 
just like the BALB/c experiments (data not shown). We concluded that proper 
immune responses may not be feasible in an immunodeficient host because 
germinal center formation depends on the orchestration of many different 




Figure 4.7: MZ B cells may be capable of seeding germinal centers after 
gp120 immunization.  
CD4 T cells were FACS sorted to >99% purity from day 30 gp120/alum mice. 
Naïve FO and MZ B cells were FACS sorted to >95% purity. 2x105 CD4 T cells 
and 1x106 FO or MZ cells were transferred i.v. into B6.129S7-Rag1tm1Mom/J mice 
which were then immunized with 10 µg gp120 in alum. One mouse was left 
unimmunized as a control. Mice were sacrificed 14 days after transfer and 
immunization. a) Phenotypic analysis of CD11c-CD3-Igκ+ B cells. Representative 
plots show germinal center (top row; PNA+IgD-) and class-switched (bottom row; 
IgG1+) B cells. b) Graphical summary of percentage of CD4 T cells, germinal 
center B cells, and class-switched B cells. c) Serological analysis of total IgM, 
total IgG and gp120-specific IgG. 
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Analysis of responding anti-HIV B cells 
 To examine B cells during a response to gp120, we again turned to flow 
cytometric analyses. The original goal was to evaluate the magnitude and quality 
of the B cell response with alum and then compare it to other adjuvants, such as 
TLR agonists. As a first step, we had to be confident in our ability to detect 
responding gp120-specific B cells. 
 We first analyzed primary immune responses of mice immunized with 10 
µg gp120 in alum. We found that the most reliable way to detect antigen specific 
cells was to gate on plasma cells, which are larger than naïve B cells and 
express high levels of Ig (almost 20% of total cellular protein). Plasma cells 
therefore were defined as intracellular IgκhiFSChi (Fig 4.8.a, top row), and then 
analyzed for the terminal differentiation marker CD138 and antigen binding with 
intracellular gp120-647 (Fig 4.8.a, bottom row). Seven days after immunization, 
control mice that were immunized with alum alone and experimental mice that 
were immunized with gp120 and alum both have a distinct plasma cell population 
that is CD138+. However, intracellular gp120 staining is only found in plasma 
cells of antigen-exposed mice. This is also true when mice are immunized with 






Figure 4.8: gp120 binding is only detectable in plasma cells of gp120-
exposed mice.  
a) Mice were immunized with alum alone or 10 µg gp120 in alum and sacrificed  
7 days later. Splenic plasma cells (top row; FSChi intracellular Igκhi) are assessed 
for intracellular gp120 staining (bottom row). Representative of 4 experiments. b) 
Mice were immunized with 10 µg OVA in alum or 10 µg gp120 in alum and 
sacrificed 7 days later. Plasma cells (top row; FSChi intracellular Igκhi) are 
assessed for intracellular gp120 staining (bottom row). Representative of 2 
experiments. 
 
 We also analyzed slightly later time points of the primary response. At 10 
days post immunization we could no longer reliably detect antigen-specific 
plasma cells in the spleen (data not shown). Instead we analyzed long lived 
plasma cells in the bone marrow, which are differentiated B220-Igκ+ cells [143] 
(Fig 4.9). Plasma cells in mice that received alum alone (gray gate) are IgM+ and 
do not bind gp120 intracellularly. Plasma cells in mice that received gp120 in 
alum (colored gates) are often IgM-, indicating class switching, and bind gp120. 
One of the three mice in this experiment does not have IgM-gp120+ cells (purple 
gate). As this mouse did not even have a discernable plasma cell population like 
the other mice, it may not have had a robust response, or possibly was 
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improperly immunized. The levels of gp120 staining in the plasma cell 
populations are also shown as a histogram to aid in a direct comparison. We 
conclude that gp120-specific responding B cells are readily detectable as plasma 




Figure 4.9: Long lived plasma cells are generated by gp120 immunization.  
a) Mice were immunized with alum alone or 10 µg gp120 in alum and sacrificed 
10 days later. Bone marrow (long lived) plasma cells (top row; B220- intracellular 
Igκ+) were analyzed for intracellular IgM expression and intracellular gp120 
staining (bottom row). A histogram of plasma cell gp120 binding is included to aid 
in direct comparison. Gray gate is from the alum mouse and colored gates are 






 We then proceeded to studying anti-gp120 responses with viral-like 
particles (VLPs), which should display the HIV antigens in a more physiologically 
relevant manner. In addition to gp120, the VLPs have other antigens such as 
gp41, which we have not analyzed. We were first interested in what types of B 
cells are able to respond to and recognize gp120 after VLP immunization. We 
examined early time points in the primary response (days 5-7). Unfortunately, we 
were never able to detect an increase in B cell gp120 binding in VLP/alum-
immunized mice, even when using intracellular staining (Fig 4.10, top row). We 
did analyze the phenotype of B cells capable of recognizing gp120 (blue gates), 
and found that they were mostly FO B cells (Fig 4.10, bottom row), similar to the 
phenotype of gp120-binding cells in unimmunized mice.  
       
 
Figure 4.10: No increase in gp120 staining is seen in VLP-immunized mice.  
Mice were immunized with VLPs in alum and then sacrificed 5-7 days later. Plots 
are pregated on singlet lymphocyte-sized splenocytes. The phenotype of gp120-
binding B cells (blue gate, top row; B220+intracellular gp120+) and other B cells 
(yellow gate, top row; B220+intracellular gp120-) was assessed by CD21 and 
CD1d staining (bottom row). n=1 experiment, 3 mice (1 naïve and 2 immunized) 
per time point. 
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 To see if we could detect plasma cells as we had in gp120-responding 
animals, we analyzed the bone marrow of mice immunized with VLPs in alum 10 
days prior. As can be seen in Fig 4.11, plasma cells from unimmunized mice 
(gray gate) are IgM+gp120-. Mice that received VLPs in alum (colored gates) 
have class switched IgM- plasma cells, but only one of the mice has strong 
gp120 recognition. The other two mice could have been dominantly responding 
to another epitope in the VLPs, such as gp41. 
 
Figure 4.11: Not all VLP-immunized mice generate long lived gp120-specific 
plasma cells.  
a) Mice were immunized with VLPs in alum and sacrificed 10 days later. Bone 
marrow (long lived) plasma cells (top row; B220- intracellular Igκ+) were analyzed 
for intracellular IgM expression and intracellular gp120 staining (bottom row). A 
histogram of plasma cell gp120 binding is included to aid in direct comparison. 
Gray gate is from the unimmunized mouse and colored gates are from 




 In naïve mice, we found that MZ B cells preferentially use IGHV1-53 to 
recognize gp120 (Table 3.2 and Fig 3.13). To determine if IGHV1-53-bearing B 
cells would actually participate in an anti-HIV immune response, hybridomas 
were fused from splenocytes at different time points following VLP immunization. 
Mice were immunized i.p. with VLPs in alum and splenocytes were harvested 4, 
7, 14, and 21 days later for hybridoma fusion (day 7 analysis was performed with 
a different batch of VLPs than the other time points). Three to four mice were 
used at each time point. Efficacy of VLP immunization was confirmed by 
measurement of anti-gp120 IgG in the sera. Unimmunized mice or mice 
harvested 4 days after VLP immunization do not have detectable anti-gp120 IgG 
as determined by ELISA, while mice harvested at later time points following VLP 
immunization have circulating anti-gp120 IgG (Fig 4.12).  
 
 
Figure 4.12: Anti-gp120 IgG is detectable in the sera of VLP-immunized 
mice.  
Anti-gp120 IgG was measured by ELISA. Shown are representative sera from 
unimmunized and VLP-immunized mice at different timepoints. 
 
 Hybridomas were screened for gp120 reactivity by ELISA. Overall there 
was a very low percentage (~1%) of gp120-reactive hybridomas produced from 
these fusions. At day 4 and day 21, only 2 hybridomas were isolated that 
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recognized gp120; these hybridomas produced IgM antibodies. A greater number 
of hybridomas were generated at day 7 and day 14, which are more in the peak 
of the primary antibody response. Hybridomas from these timepoints were IgM 
as well as IgG. The IGH gene segments and CDRH3 junction are shown in 
Tables 4.1-4.4. Rows are color coded based on IGHV usage. While the IGHV1 
family is used prevalently, IGHV1-53 was not detected. 
 
Table 4.1: Day 4 VLP anti-gp120 antibodies. 
 
 





Table 4.3: Day 14 VLP anti-gp120 antibodies. 
 
 
Table 4.4: Day 21 VLP anti-gp120 antibodies. 
 
Tables 4.1-4.4: Anti-gp120 repertoire of the primary VLP response. 
Mice were immunized with VLPs in alum and sacrificed 7 or 14 days later. 
Splenocytes were fused and surviving hybridomas were screened for gp120 
reactivity by ELISA. The Ig heavy chain of each hybridoma was identified using a 
PCR strategy that selectively amplifies most mouse VDJ rearrangements. Rows 
are color coded by IGHV family. Reading frame of the IGHD segment is indicated 
by parentheses. Asterisk next to a clone name denotes CDRH3 mutation. 
 
 As few hybridomas were generated at day 4 and day 21, only day 7 and 
day 14 sequences were compared graphically. As Fig 4.13.a shows, IGHV1 
dominates the response at day 7 and day 14. Additionally, there is a strong 
preference for IGHD2 gene segments at day 14. When the IGHV1 gene 
segments are analyzed individually, there is no skewing towards a particular 
gene segment at either time point (Fig 4.13.b). Again, although IGHV1-53 was 
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observed in the naïve anti-gp120 hybridoma repertoire, this segment was not 




Figure 4.13: Repertoire analysis of gp120-reactive hybridomas from VLP-
immunized mice.  
a) Heavy chain V (left), D (middle) and J (right) gene families used by day 7 VLP 
(solid) and day 14 VLP (hatched) hybridomas. b) IGHV1 family member usage by 
day 7 VLP (solid) and day 14 VLP (hatched) hybridomas. 
 
 Hybridoma fusion is dependent on cell proliferation. Accordingly, the gene 
segments analyzed here are likely from plasmablasts, whose B cell subset 
identity as naïve cells is unknown. One clue to an antibody’s origin is the length 
of the CDRH3. MZ B cells generally have a shorter CDRH3 due to decreased Tdt 
activity during B cell development [85]. To determine if these hybridomas were of 
FO or MZ origin, the CDRH3 lengths were compared to the naïve gp120-reactive 
hybridomas. For these analyses, data from all VLP timepoints were combined. 
Fig 4.14.a compares the CDRH3 lengths of naïve MZ B cell gp120-reactive 
hybridomas (open) to the VLP hybridomas (solid). The CDRH3 lengths of the MZ 
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B cells are shorter, with a skewing toward 8 amino acid lengths. In contrast, Fig 
4.14.b compares CDRH3 lengths from naïve FO B cell gp120-reactive 
hybridomas (gray) to VLP hybridomas (solid). The distribution of CDRH3 lengths 
in these populations is much more similar, indicating that the antibodies analyzed 




Figure 4.14: The responding cells analyzed following VLP immunization 
were likely FO B cells.  
a) Comparison of CDRH3 lengths between naïve MZ B cell gp120-reactive 
hybridomas (open) and VLP-immunized hybridomas (solid). b) Comparison of 
CDRH3 lengths between naïve FO B cell gp120-reactive hybridomas (gray) and 
VLP-immunized hybridomas (solid). P values are derived from a student’s t test. 
 
VLP quality assessment 
 The VLPs are produced by transient transfection of COS7 cells. Two days 
after transfection, the supernatant is collected and purified by high speed 
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centrifugation through a glycerol cushion. The VLPs, which were developed by a 
collaborator, were tested by western blotting with HIV seropositive human sera 
for HIV proteins. Although these VLPs had already been published in the 
literature [36, 37], we felt the need to more thoroughly assess their composition.  
We started by examining the transfection efficiency. COS7 cells were 
grown on microscope chambers and transfected with 5 µg VLP plasmid in 
Lipofectamine. They were then assessed by immunofluorescent histology 24 
hours later. As can be seen in Fig 4.15.a, the secondary anti-mouse IgG FITC 
alone does not have any background staining. Also, the positive control, anti-
SV40 (which is expressed ubiquitously by COS7 cells), stains all of the COS7 
cells. In contrast, anti-gp120 staining is detectable, but present on only a minority 
of cells. To better understand the percentage of infection, we developed an 
intracellular flow cytometry assay (Fig 4.15.b). COS7 cells were either 
transfected with 5 µg VLP plasmid in Lipofectamine (red line) or Lipofectamine 
alone (gray line). Twenty-four or forty-eight hours later, the VLP-transfected and 
control cells were fixed and permeabilized and stained for gp120. As seen in Fig 
4.15.b, more cells are producing gp120 at 24 hours (19%) than 48 hours (11%). 
To analyze the protein products from VLP transfection, we developed a 
unique sandwich ELISA. The plate was coated with sheep anti-gp120 polyclonal 
antibody and then blocked with bovine serum albumin (BSA). VLP products 
(either supernatant or glycerol-purified material) were then added. The detection 
antibody used was a human anti-gp41 monoclonal antibody (4E10). The ELISA 
was then developed with an anti-human IgG-AP and phosphatase. As can be 
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seen in Fig 4.16.a, a strong signal is detected with either supernatant from VLP-
transfected cells or the purified material. No signal is detected from the 
supernatant of cells that only received Lipofectamine (“blank”). This assay 
instilled confidence that multiple HIV genes were being produced, and 
furthermore that they were associated together. 
 
 
Figure 4.15: COS7 cells produce detectable gp120 following VLP 
transfection.  
a) COS7 cells were grown in microscope chambers and transfected with 5 µg 
VLP plasmid in Lipofectamine. 24 hours later cells were stained for DAPI (blue) 
and SV40 or gp120 (green). The secondary anti-mouse IgG FITC has no 
background staining (top). All COS7 cells have detectable SV40 (middle left) and 
some produce gp120 (middle right). The cells producing gp120 are in the 
minority (bottom). b) COS7 cells were harvested 24 or 48 hours after transfection 
with 5 µg VLP plasmid in Lipofectamine (red line) or Lipofectamine alone (shaded 
gray line). Cells were fixed and permeablized and stained with mouse anti-gp120 






Figure 4.16: VLP transfection produces HIV proteins that associate 
together.  
a) A sandwich ELISA was developed to determine if the HIV proteins were 
associated with each other. Sheep anti-gp120 polyclonal antibody was coated on 
high binding plates at 2 µg/mL. Wells were then blocked with 1% BSA. Samples 
(either supernatant or glycerol-purified products) were then added to the wells. 
Anti-gp41 human monoclonal antibody was serially diluted down the plate with a 
starting concentration of 10 µg/mL. Anti-human IgG-AP was used for detection 
and the ELISA was developed with phosphatase. b) Glycerol-purified VLP 
products were diluted in PBS into a microcuvette. Dynamic light scattering was 
used to determine the size of the VLP products. 
 
According to the laboratory that developed these VLPs, they band 
between 32 and 40% sucrose on a density gradient, “similar to wildtype virions” 
[36]. HIV virions are approximately 100 nm in diameter [10, 11]. To measure the 
size of the VLPs, we employed dynamic light scattering (DLS), with the aid of Dr. 
Wei Qi at the University of Colorado School of Pharmacology. DLS measures the 
hydrostatic size of particles in motion by shining a light beam and measuring the 
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change in wavelength when the light hits a particle in a solution. After resolving 
some issues in our sample preparation (e.g., phenol red interferes with DLS and 
can not be used in the media during transfection), we were able to measure the 
size of the particles in our glycerol-purified product (Fig 4.16.b). Overall, the 
particles were not very abundant in the solution (less than 20% of the overall 
composition). The major peak, 15% of the solution, was at approximately 80 nm, 
close to the size of HIV. There was another peak, comprising 5% of the solution, 
which was about 10 times bigger. This peak may represent aggregates of VLPs. 
The true test of VLP structure, of course, is visualization by electron 
microscopy. Glycerol-purified products from VLP or “blank” transfected cells were 
applied to formvar-coated grids and stained with 2% uranyl acetate. When 
analyzing the samples by electron microscopy, there were large aggregations of 
proteins that were structureless (data not shown). However, viral structures with 
clear membranes were detectable in VLP-transfected material (Fig 4.17, top 
row). Unfortunately, these same viral structures were detected in cells that were 
transfected with Lipofectamine alone (Fig 4.17, middle row), indicating that they 
were not likely VLPs. Apparently fetal bovine serum, used to supplement the cell 
culture media, may contain viruses [144] and this is likely what we were imaging. 
To circumvent this, COS7 cells were transfected using serum free (SF) media. 
Here viral structures were also detected (Fig 4.17, bottom row), but they were 
less structurally sound, potentially indicating that the COS7 cells need fetal 
bovine serum to properly produce VLPs. These data would indicate that although 
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HIV gene products are being produced, they are not in a viral-like configuration. 
Thus, we have not pursued further studies with these VLPs. 
Tracking IGHV segments during an immune response 
 Although people exposed to HIV by infection or vaccination are able to 
develop high titers of antibody to viral proteins, these antibodies are generally 
non-neutralizing and therefore not protective [44]. For HIV, quantity is not the be-
all end-all; antibody quality appears to be an important factor. One interpretation 
of “quality” is the ability to neutralize a wide range of viruses. The human IGHV1-
2*02 segment has been found in multiple broadly neutralizing antibodies from 
different subjects. One antibody that employs IGHV1-2*02, VRC01, is able to 
neutralize over 90% of HIV strains in vitro [67]. One way to make an effective 
vaccine could be to preferentially encourage the participation of IGHV1-2*02-
bearing B cells to generate VRC01-like antibodies. We have identified the mouse 
IGHV1-53 as the ortholog of human IGHV1-2*02 and were interested in 
developing a readout to track the use of IGHV1-53 in an immune response.  
 To accomplish this, we turned to a real time polymerase chain reaction 
(RT-PCR) approach using primers that specifically amplify IGHV1-53. 
Responding B cells proliferate as they differentiate into plasma cells, which also 
have a much higher production of Ig transcript and antibodies. Thus, if IGHV1-
53-bearing B cells are participating in an immune response, IGHV1-53 transcript 
levels should be higher than those in control mice. Alternatively, if IGHV1-53 B 
cells are relatively unresponsive, IGHV1-53 transcript levels will be depressed if 












Figure 4.17: The majority of material in “VLPs” is not in virion form.  
Glycerol-purified products from VLP or blank transfected cells were added to 
formvar-coated grids and stained with 2% uranyl acetate. Electron microscopy 









To begin the validation of this assay, mice were immunized with alum or 
10 µg gp120 in alum and sacrificed 5 days later. RNA was harvested from 2x106 
splenocytes, reverse transcribed into cDNA and then analyzed by RT-PCR. At 
this point in the primary response, B cells will be in the plasmablast or plasma 
cell stage, and restricted largely to the spleen or draining lymph nodes. Several 
experiments led to conflicting results. Overall, there was very low magnitude of 
detection for IGHV1-53, and no consistent differences between control and 
experimental mice (Fig 4.18). 
 
Figure 4.18: IGHV measurement from whole spleen is variable.  
Mice were immunized with alum alone or 10 µg gp120 in alum and sacrificed 5 
days later. RNA was harvested from 2x106 whole splenocytes and reverse 
transcribed into cDNA. IGHV1-53 was measured by RT-PCR. Representative of 
6 experiments. 
 
 Given these weak initial results, we sought to stack the odds in our favor 
in two different ways. First, to generate a more robust signal from responding 
cells, we enriched for CD138+ cells using anti-CD138 PE and anti-PE beads on a 
magnetic column. CD138 is expressed by terminally differentiated plasma cells 
that are secreting high levels of antibody. Thus, CD138 enrichment will capture 
the majority of responding cells, instead of just analyzing whole splenocytes. Fig 
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4.19.a shows the enrichment of CD138+ cells from whole splenocytes to the 
column-bound fraction (over 30-fold). As can be seen in the left panel of Fig 
4.19.b, the approach of enriching for CD138+ cells increased the IGHV signal 5-
15-fold over whole splenocytes. Additionally, we decided to move to a system 
with well defined IGHV responses, the 4-hydroxy-3-nitrophenyl (NP) hapten 
system. Since we already know that in a C57BL/6 mouse IGHV186.2 is the 
dominant clonotype in the primary NP antibody response [121, 145], this system 
essentially allows us to test the validity of our assay. Mice were immunized with 
alum alone or 100 µg NP-CGG in alum and sacrificed 5 days later. Splenocytes 
were then enriched for CD138 expression and IGHV186.2 was measured by RT-
PCR. Although the CD138 enrichment was successful in increasing the 
magnitude of signal, VH186.2 expression measured by RT-PCR was still not 
consistent between control and experimental mice (Fig 4.19.b, right panel). 
It appeared that although CD138 enrichment increased the signal, it was 
increased relative to the starting signal of whole splenocytes, which was variable. 
We then compared IGHV1-53 expression from control mice from three different 
experiments and found a 3-fold difference (Fig 4.20). If this 3-fold difference in 
starting expression is then amplified by CD138 enrichment, consistent and 
reliable results will be hard to obtain. Although an intriguing approach, this assay 
does not appear to be a viable way to track specific clonotypes during an 















Figure 4.19: CD138 enrichment increases the IGHV signal.  
Mice were immunized with alum alone or 100 µg NP-CGG in alum and sacrificed 
5 days later. a) Splenocytes were stained with anti-CD138 PE and then 
incubated with anti-PE beads. Cells were then run over a magnetic column and 
stained for B220. Plots pregated on singlet lymphocyte-sized cells show the 
unenriched (left), column-bound (middle) and flow through (right) fractions.        
b) IGHV186.2 was measured by RT-PCR. The increase in IGHV186.2 signal by 
CD138 enrichment was calculated by dividing the signal from the column-bound 
fraction by the signal from the unenriched fraction (left). Although the signal was 
increased by CD138 enrichment, there is still no consistent difference between 






Figure 4.20: Baseline expression variability of IGHV may preclude this type 
of analysis.  




 A major limitation of formally assessing the MZ contribution to class- 
switched high affinity antibodies generated from germinal center reactions is that 
the phenotype distinguishing them from FO B cells disappears upon antigen 
recognition and cell differentiation. To try to understand how long MZ B cells 
maintain their phenotype, FTY720 was used to force them into the follicle. 
Although CD21 was briefly downregulated (Fig 4.1), no long term changes were 
seen (Fig 4.2), indicating that mere location is not enough to cause MZ B cells to 
alter their coreceptors. So, the most direct way to evaluate their function is to do 
adoptive transfers of different B cell subsets. Attempts to purify greater numbers 
of MZ B cells were fruitless (Fig 4.3 and 4.3), maintaining the great amount of 
time and resources needed to purify MZ B cells.  
 Previous attempts to adoptively transfer MZ B cells into wildtype mice 
have shown that transferred MZ B cells do not localize to the marginal zone. 
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Attempts were made to “make room” for the transferred cells by using anti-
integrin antibodies to deplete the host mice 10 days prior to transfer. These 
results showed that not only did the transferred MZ B cells not localize properly, 
they did not maintain their phenotype (Fig 4.5).  
To recapitulate experiments showing MZ germinal center formation from 
other laboratories [98, 99], we then turned to transferring MZ B cells into B cell 
deficient hosts. This resulted in barely detectable antigen-specific immune 
responses and completely disorganized splenic architecture (Fig 4.6 and 4.7). 
Studies have shown that lymphotoxin beta (LTβ) produced by B cells is crucial 
for proper lymph node development and FDCs [139, 146]. Therefore, by 
specifically transferring B cells into a mouse that does not have FDCs or proper 
lymphoid organization, inducing robust germinal center formation may be an 
unreasonable goal. In the future we will use MD4 x AID-/- mice as hosts. These 
mice will be advantageous because they will have a fixed BCR repertoire for HEL 
and B cells that cannot class switch or undergo hypermutation. Therefore, we 
can safely attribute any IgG or mutated response to the transferred cells, which 
will have enjoyed a proper lymphoid environment, as well as contact with FDCs 
and CD4 T cells. 
We developed flow cytometric assays to analyze gp120-specific B cells 
during an immune response (Fig 4.8 and 4.9). Mice immunized with alum alone 
or a control antigen in alum did not have gp120-binding plasma cells, while a 
significant portion of the plasma cells in gp120-immunized mice bound gp120 
intracellularly. When these techniques were applied to VLP-immunized mice, less 
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consistent and weaker responses were detected (Fig 4.10 and 4.11). One 
possibility for this is that there are many antigens in the VLPs, and we were only 
probing gp120-specific responses. This is exemplified in Fig 4.11, where all three 
VLP-immunized mice have class switched plasma cells in the bone marrow 10 
days after immunization, but only one mouse has plasma cells that bind gp120. It 
is possible that the other two mice are dominantly responding to another antigen, 
such as gp41. When the repertoire of anti-gp120 antibodies from VLP-immunized 
mice was analyzed at different timepoints (Tables 4.1-4.4 and Fig 4.13), there 
was no preferential use of any IGHV gene segments as had been seen in naïve 
mice (Table 3.2 and Fig 3.13). Additionally, based on CDRH3 length, it seems 
that these VLP antibody responses were dominated by FO B cells (Fig 4.14). 
After conducting many studies with these VLPs and not getting the 
expected results, we decided to further investigate the quality of this antigen. We 
found that although transfections using the VLP plasmids were producing HIV 
proteins (Fig 4.15 and 4.16), these proteins were largely not in a viral form, as 
shown by electron microscopy (Fig 4.17). Therefore, we have stepped away from 
using these VLPs as the main draw was physiological epitope presentation. In 
the future we will pursue an immunization strategy with a polymerized form of the 
CD4 binding site epitope of gp120. 
Finally, we tried to develop an assay to follow IGHV segments at a 
molecular level. Measuring IGHV1-53 from splenocytes did not give a high 
magnitude of signal or consistent differences between control and experimental 
mice (Fig 4.18). To increase the signal of IGHV detection, we used magnetic 
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column enrichment to select for CD138+ cells (Fig 4.19). We also moved to 
measuring IGHV186.2, the dominant IGHV in NP responses in C57BL/6 mice. 
Although the CD138 enrichment increased the magnitude of signal, we could not 
reliably detect an increase in IGHV186.2 expression in mice immunized with NP 
(Fig 4.16). When comparing the levels of IGHV1-53 expression in control mice 
immunized with alum alone, a 3-fold difference was seen (Fig 4.20). This 
difference is easily magnified by CD138 enrichment, which increases the signal 
5-15 fold. Therefore, it appears that this assay is not appropriate for our goals. In 
the future we will pursue deep sequencing of IGHV segments in immunized mice 








HIV vaccine development may benefit from the targeting of a non-dominant 
B cell subset 
HIV, as a successful pathogen, has spent its existence developing 
mechanisms to evade the immune system. One viral protein, Nef, avoids CD8 T 
cell detection by shuttling MHC class I to endosomes for degradation [147, 148]. 
Subsequent NK cell detection is avoided by not interfering with other MHC 
molecules that serve as inhibitory receptors for NK cells. In turn, the envelope 
protein gp120 is particularly adept at attracting antibodies that are unable to 
prevent viral infection. A large proportion of antigen available is in the form of 
disassembled virions [149], leading to the production of antibodies that do not 
bind the intact envelope trimer. The immunodominant epitopes of gp120 are the 
variable loops [46], which mutate rapidly and have great genetic distance 
between strains. More protective epitopes such as the CD4 binding site are 
conformationally unavailable on free virions, making protective antibodies 
targeting this epitope during a primary response an unlikely occurrence; these 
antibodies are detected two to three years after infection [150]. About three 
quarters of HIV infections are transmitted by only a single founder virus [43]. If a 
vaccine could be generated to provide circulating antibodies to inhibit that single 
virion before infection is established, the HIV epidemic could be halted. 
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To better understand which B cell subsets are capable of generating an 
anti-gp120 antibody response, we analyzed FO and MZ B cell populations from 
naïve mice and uninfected humans. To identify B cells capable of recognizing 
gp120, we relied on flow cytometric analyses. Specifically, we used magnetic 
column enrichment to capture antigen-reactive B cells for further phenotyping 
[125]. The binding seen by B cells with our antigen is likely mediated by the B cell 
antigen receptor (BCR), as binding was abrogated by fixing the BCR specificity 
(Fig 3.4). Experiments conducted with murine (Fig 3.9) and human (Fig 3.17) 
splenocytes indicated that the majority of B cells capable of recognizing gp120 
were of follicular or naïve origin, respectively.  
As FO B cells outnumber MZ B cells in both mice and humans, this 
indicates that based on frequency, any encounter with gp120, be it on a virion or 
in a vaccine, would likely be with a FO B cell. In the course of these studies, HIV 
viral-like particles (VLPs) were administered in alum and the repertoire of 
responding anti-gp120 antibodies was analyzed at different time points in the 
primary response (Fig 4.13). Based on CDRH3 lengths, the responding cells 
were most likely originally FO B cells. Given that the primary anti-gp120 antibody 
response does not generate neutralizing antibodies [44, 151], it may be the case 
that FO B cells are not suited to combat HIV. If the primary anti-gp120 response 
is dominated by FO B cells in humans, and is generally non-protective in acutely 
infected individuals, then it might be useful to consider promoting the 
participation of other B cell subsets as an HIV vaccine strategy. In this regard, a 
recent report by Dosenovic et al [152] showed that repeated treatment of mice 
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with BlyS increased the MZ compartment of mice, which was followed by a more 
robust response to HIV envelope protein immunization and an increase in the 
frequency and breadth of neutralizing antibodies.  
Abundant evidence using model antigens in rodent systems has indicated 
that MZ B cells typically mount rapid low affinity antibody responses devoid of 
mutation. While the use of these model antigens has clearly been instructive, the 
prototypical MZ B cell antigen, hapten-polysaccharide conjugates, lack a protein 
epitope, thus precluding the participation of T cells that would be required for 
germinal center formation [153]. Indeed, MZ B cells are capable of seeding 
germinal centers and undergoing somatic hypermutation [98, 99] and the 
antibody response in humans to typical MZ B cell antigens, bacterial capsular 
polysaccharides, is often mutated [103-109]. In reality, the marginal zone B cell 
contribution to pathogen challenge as class-switched, high affinity antibody from 
germinal center reactions is difficult to ascertain and largely undefined as 
antibody responses of MZ B cells in an intact mouse are currently difficult to 
follow.  
Nevertheless, there is rationale for considering the elicitation of MZ B cell 
HIV antibody responses in vaccine design. MZ B cells exhibit increased 
expression of co-stimulatory receptors compared to naïve or FO B cells, 
including complement receptor 2 (CR2/CD21) and a wider range of TLRs [87, 90, 
91]. Human MZ B cells respond more robustly to T cell-like help or TLR 
stimulation in vitro [92-95]. Rodent MZ B cells express CD1d and human MZ B 
cells express CD1c [101], allowing them to provide cognate help to a wider range 
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of T cells than FO B cells. Additionally, mouse MZ B cells upregulate antigen 
presenting molecules such as MHC and CD80/86 more readily than FO B cells 
upon stimulation, suggesting that they are particularly well suited for antigen 
presentation to cognate T cells [142]. Specifically eliciting MZ B cell responses 
could lead to enhanced cellular as well as humoral immunity. 
 
MZ B cells use a restricted repertoire to recognize gp120 that may be 
particularly beneficial for an anti-HIV antibody response 
Investigation of the molecular repertoire of gp120-binding antibodies from 
naïve murine FO and MZ B cell hybridomas revealed that MZ B cells 
preferentially used IGHV1-53 to recognize gp120 (Table 3.2 and Fig 3.13). As 
these hybridomas were generated from LPS-stimulated naïve FO and MZ B 
cells, and because MZ B cells are preferentially stimulated by LPS [96, 97], we 
independently demonstrated by quantitative RT-PCR that IGHV1-53 is also 
enriched in naïve MZ B cells (Fig 3.14). 
We next asked if IGHV1-53, preferentially used by murine MZ B cells to 
generate gp120-reactivity, was similar to any IGHV used in anti-gp120 antibodies 
found in humans. To address this, we compared the IGHV1-53 sequence to 
human IGHV sequences using several databases, including IMGT [119]. These 
results revealed that the IGHV1-53 gene segment, which is disproportionately 
used by gp120-reactive MZ B cells in the mouse, shows highest sequence 
identity with human IGHV1-2*02 and IGHV1-46*01. Notably, VRC01 and related 
broadly-neutralizing anti-gp120 antibodies are encoded by IGHV1-2*02, while 
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other broadly neutralizing antibodies have been shown to use IGHV1-46*01 [68]. 
At the nucleotide level, mouse IGHV1-53 is 78% identical to human IGHV1-2*02, 
and the encoded protein sequences are 70% identical and 85% similar 
hydrophobically (Fig 5.1.a). In comparison, mouse IGHV1 family members are on 
average only 63% identical to human IGHV1 family members at the protein level 
[154], suggesting this high identity / similarity between murine IGHV1-53 and 
human IGHV1-2*02 is not strictly a result of family relatedness.  
 
Figure 5.1: The mouse IGHV1-53 is orthologous to the human IGHV1-2*02.  
a) Amino acid sequence alignment encoded by germline murine IGHV1-53*01 
(top) and human IGHV1-02*02 (bottom) genes. Identities are shown with a line 
and similarities with a + and identical CDRH2 residues are in red. Below the 
CDRH2 region, * indicates residues mutated in VRC01 and black circles indicate 
residues involved in interaction with gp120. b) Mouse IGHV1-53*01 (left), human 
IGHV1-2*02 (center) and the mature mutated VRC01 VH (right) regions. Black 
circles identify amino acids identical in all three IGHV segments, red circles 
indicate identity between murine IGHV1-53 and human IGHV1-2*02, gray circles 
indicate identity between IGHV1-2*02 and the mature VRC01, and white circles 




Figure 5.1.b highlights the similarities between the mouse germline 
IGHV1-53, human germline IGHV1-2*02 and human mature IGHV of VRC01 
based on the Collier de Perles configuration [155]. Amino acids common to all 
three IGHV are in black, those shared only by IGHV1-2*02 and IGHV1-53 are in 
red, and those shared only by IGHV1-2*02 and the mature VRC01 are in gray. At 
the protein level, IGHV1-2*02 and murine IGHV1-53 are 70% identical while 
IGHV1-2*02 and the mature VRC01 are only 58% identical; over 40% of amino 
acids are identical between all three IGHV-encoded sequences. Notably, two 
residues important for contact with gp120 that are conserved between the 
germline IGHV1-2*02 and the mature VRC01, Tryptophan 50 and Arginine 72 
[75, 156], are not found in the murine IGHV1-53. 
VRC01 has been crystallized with a gp120 core protein [75]. This crystal 
structure revealed that over half of the contact by VRC01 with gp120 is within the 
IGHV1-2*02-encoded and mutated CDRH2 region, likely accounting for the bias 
in broadly neutralizing activity for IGHV1-2*02-encoded IgH chains, independent 
of the IGHD and IGHJ segments [68, 76]. In support of the importance of this 
CDRH2 region, IGHV1-2*02-encoded IgH chains can pair with diverse IgL chains 
and still provide neutralizing activity [68, 76] and the mouse ortholog IGHV1-53-
encoded IgH chains can pair with diverse IgL chains to encode anti-gp120 
reactivity (Fig 3.12). Notably, the CDRH2 protein sequence encoded by the 
murine germline IGHV1-53 is highly similar to IGHV1-2*02 and differs only by an 
inversion of two amino acids to the human germline sequence (Fig 5.1).  
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An obvious difference between the human and mouse genes is that the 
germline mouse IGHV1-53 is able to confer binding to gp120, while germline 
human IGHV1-2*02 apparently does not [59, 67]. More specifically, when the 
IGHV1-2*02-encoded broadly neutralizing VRC01 and related antibodies were 
reverted back to the putative germline sequences and tested by ELISA and 
surface plasmon resonance, minimal to no binding was observed to gp120 [67, 
68, 76]. However, these germline revertants were all tested for gp120-reactivity 
as bivalent IgGs with only the V segments reverted to germline. The murine 
antibodies were derived as pentavalent IgM. In this case, low affinity of germline 
binding could be compensated for by an increase in avidity. Additionally, the 
CDRH3 lengths of the murine IGHV1-53 antibodies are 3-4 amino acids shorter 
than VRC01. This shorter CDRH3 length could allow the CDRH2 to gain better 
access to gp120 and promote binding. 
Moreover, we would argue that serological readouts of secreted antibody 
are markedly different than crosslinking of IgM, or IgD with its relatively flexible 
hinge region, expressed as an antigen receptor on the surface of a naïve B cell. 
Recently, germline VRC01 in the context of IgM BCR on a B cell line did not 
mediate upregulation of CD69 in response to HIV pseudovirus, unlike the mature 
VRC01 BCR [59]. Finally, it is also clear that given the stochastic nature of V-D-J 
recombination, including the addition of non-templated nucleotides and loss of 
germline-encoded nucleotides within the CDRH3, the precise sequence of the 
germline VRC01 IgH and IgL chains is uncertain. It is also of interest that the 
affinity of VRC01 and related antibodies for gp120 is perhaps lower than what 
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might be expected for the degree of somatic mutation displayed [67]. This high 
mutation rate, seen as a barrier in vaccine design, might be a consequence of 
chronic antigen stimulation and activation in the HIV disease state of the patient 
rather than borne out of necessity to enhance function. A lack of binding by 
germline IGHV1-2*02 antibodies to native gp120 may indicate that the original 
epitope recognized by these B cells was derived from disassembled virions [149].  
IGHV1-2*02-encoded broadly-neutralizing HIV antibodies have been 
isolated from circulating B cells from chronically infected subjects [67]. The 
original phenotype of the B cells that eventually produced these protective 
antibodies is unknown, and our findings would suggest that the original B cells 
could have been either FO or MZ B cells. However, we postulate that the B cells 
generating these broadly-neutralizing antibodies may have originally been MZ B 
cells. Evidence to support this include that the CDRH3 of the VRC01, 12A12 and 
3BNC60 heavy chains, and other IGHV1-2*02-encoded broadly-neutralizing 
antibodies, are much shorter than those of other broadly neutralizing antibodies 
[67, 68], a characteristic of human and rodent MZ B cells [85, 109]. Additionally, 
the IGHV1-2*02 segment has repeatedly been seen clinically as a feature of 
marginal zone lymphomas [157, 158], clearly indicating that human MZ B cells 
naturally express this IGHV gene segment. Molecular analyses of a human 
spleen sample and peripheral blood showed no preferential expression for 
IGHV1-2*02 in MZ B cells as had been detected for IGHV1-53 in mouse MZ B 
cells (Fig 3.18 and 3.19). The fact that expression appeared relatively even 
between the two human subsets is interesting, considering human MZ B cells 
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preferentially use IGHV3 segments in their heavy chains, and IGHV1 segments 
are the least used by this subset [159]. 
Qualitatively, the murine MZ B cell IGHV1-53 antibodies are polyreactive 
(Fig 3.15). Although polyreactivity is not usually a sought-after feature of 
antibodies in a vaccine response, it may be particularly beneficial for anti-HIV 
responses. The spike density of HIV is very low, with an average of 14 spikes per 
virion [58]. This results in inter-spike distances that exceed the reach of the 
antigen-binding domains of surface BCRs, making occupation of multiple BCRs 
and subsequent crosslinking rare [60]. One study expressed the BCRs of human 
broadly neutralizing antibodies in B cell lines to test their capacity to be activated 
by different HIV antigens [59]. Although b12 and VRC01-expressing cell lines 
could easily be stimulated by HIV envelope trimers, no calcium mobilization was 
detected after stimulation of even hyperphysiological concentrations of 
pseudovirus. These same pseudovirus constructs are easily neutralized by these 
secreted antibodies in vitro, indicating that there may be constraints on epitope 
recognition in the context of surface BCR. Multivalent cross-linking of surface 
BCR is a tipping point in B cell activation [160, 161], which may not be reached 
with binding to viral epitopes alone. Indeed, the paucity of viral spikes may 
necessitate the binding of multiple epitopes by surface BCRs [60, 61]. In the 
context of infection where virions bud out of cells, the secondary epitopes of this 
heterologous binding are likely to be host-derived. 
Given that germline revertants of broadly neutralizing antibodies are 
mostly unable to recognize gp120 [59, 67, 68, 76, 162], an alternative scenario 
112 
 
for the generation of broadly neutralizing antibodies may be that the original 
activating antigen is not gp120 at all. A cross-reactive or polyreactive B cell may 
get pulled into an anti-HIV response and undergo somatic hypermutation to then 
be able to bind the viral spike. However, given that IGHV1-2*02 has been found 
repeatedly in neutralizing antibodies from different subjects, it is more likely that 
the germline segment was somehow involved in an anti-HIV response. So, the 
question remains, how could a vaccine be designed to coax B cells bearing these 
IGHV1-2*02 BCRs into a gp120-directed immune response, complete with 
germinal center formation and subsequent somatic hypermutation? 
B cells are not a homogenous population. B cell subsets serve distinct 
functions, and even harbor different BCR repertoires. Repertoire-specific and 
specialized B cell subset protection has been observed for other human 
pathogens such as rotavirus [163] and Streptococcus pneumoniae [102]. New 
techniques in isolating anti-gp120 broadly neutralizing antibodies [68, 159] have 
led the scientific community to the IGHV1-2*02 segment, which has the potential 
to generate protective antibodies against a wide range of HIV strains. A recent 
study on the immune correlates in the RV144 vaccine trial reported that infection 
risk was inversely correlated with antibody-dependent cellular cytotoxicity 
(ADCC) activity [31]. Similar methods of antigen-specific B cell sorting were used 
to isolate ADCC antibodies from multiple vacinees. Of the 21 antibodies 
sequenced, 12 were encoded by either IGHV1-2*02 or IGHV1-46*01. These 
antibodies had low levels of mutation rates (average of 2.4%) and interestingly, 
some had short (e.g. 12 amino acid long) CDRH3s. These results would indicate 
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that vaccine stimulation of MZ B cells bearing BCRs encoded by protective 
clonotypes is possible. 
 
The way forward for HIV vaccine development 
HIV is a primarily mucosal infection. IgG is the dominant isotype in the 
human genital tract, and arrives by paracellular diffusion of serum through the 
epithelia [164]. This IgG is derived from systemic immune responses, indicating 
that classical methods of immunization may be effective [165, 166]. However, 
vaccine development may be furthered by intranasal routes of administration to 
encourage lymphocyte homing to mucosal surfaces [167].  
One of the shortcomings of HIV vaccine development is the tendency to 
look for clues about protective immunity in convenient places. Serological studies 
are often conducted on chronically infected individuals. Aside from the demolition 
of the CD4 T cell compartment, B cells have been bathing in cytokines and 
antigen for years. HIV infection causes hyperactivation, hypergammaglobunemia, 
exhaustion, and even disruption of B cell subsets and antibody repertoire [165, 
168-170]. The antibodies generated in these individuals are not comparable to 
what would be produced in a healthy recipient of an HIV vaccine. We feel it is 
important to study the pre-immune repertoire to HIV to assess what B cells are 
available for a vaccine response.  
Another group of subjects, long-term non-progressors, are also studied. 
Although these people have not progressed to AIDS, their immune systems did 
at one time allow HIV infection, and virus persists in their system. The most 
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interesting (and perhaps enlightening) cohort to study would be individuals that 
are repeatedly exposed to HIV and never become infected. These cohorts exist, 
often in the form of sex workers in low-income countries where HIV is endemic.  
More in-depth studies of the mucosal repertoire [166, 171] of these individuals 
are needed to define concrete parameters of HIV resistance. 
Following the failure of the Merck vaccine, there has been a call for 
refocusing on the way HIV vaccine candidates are advanced [172, 173]. There 
are many steps in between a naïve B cell recognizing its antigen and the 
secretion of class-switched, high affinity antibody capable of neutralizing virus. 
For the goal of broadly neutralizing antibody production, construction of anti-HIV 
broadly neutralizing antibody knock-in mice [174] or B cell lines bearing germline-
reverted versions of broadly neutralizing antibodies [59] provides a useful method 
to test candidate vaccines. In this way, the stimulation of desired B cells can be 
assessed by BCR crosslinking and activation. If the vaccine candidate is unable 
to stimulate these cells, it is unlikely to elicit protective humoral responses in vivo. 
Before clinical trials are undertaken, functional assays of protection instead of 
phenotypic readouts must be established. We need to assay target cell killing by 
CD8 T cells instead of interferon gamma ELISpots; virus neutralization by serum 
antibodies instead of gp120-binding ELISA titers. Redirecting the focus of 
vaccine candidate testing to functional readouts will surely aid in eliminating 
vaccines that will be unable to generate truly protective responses to HIV. 
Although IGHV1-2*02 antibodies have been isolated from multiple 
individuals, the events leading to the generation of these heavily mutated 
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antibodies are unknown. To some extent, replicating the exact genesis of these 
antibodies is unnecessary. The immune system in an HIV-infected individual, 
regardless of their progression to AIDS, is substantially different than the immune 
system of a healthy person receiving a vaccine. Classical methods of testing 
antigen reactivity of partially germline-reverted IGHV1-2*02 antibodies (gp120 
binding by ELISA) have yielded negative results. Of course, this is true for 
germline versions of other broadly neutralizing antibodies such as b12 [162]. If a 
lack of germline reactivity is a global phenomenon as opposed to a specific 
phenomenon with IGHV1-2*02 antibodies, then innovative structural design is 
needed for HIV vaccine development. Antigens must be constructed that can 
elicit germinal center responses from low-affinity germline precursors and drive 
selection of B cells that are able to generate broadly neutralizing antibodies. 
The heavily mutated CDRH2 of VRC01 is responsible for targeting the 
CD4 binding site of gp120; only 2 of the 8 amino acids are conserved from 
germline IGHV1-2*02 in the mature VRC01. Perhaps a prime-boost strategy with 
differently designed gp120 antigens could enhance somatic hypermutation of 
IGHV1-2*02 antibodies. The first antigen would be able to stimulate the germline 
B cells into seeding germinal centers. Two months later, a related, but altered, 
gp120 would be administered that preferentially binds a mutated IGHV1-2*02 
CDRH2. This second antigen would preferentially target the memory B cells from 
the first immunization harboring potentially useful mutated BCRs into another 
round of germinal center reactions and somatic hypermutation.  
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As the murine IGHV1-53 CDRH2 is very similar to IGHV1-2*02 (differing 
only by an inversion of two amino acids), the mouse model may prove valuable in 
testing candidate antigens for this purpose. Although the CDRH2 is important for 
gp120 recognition across diverse strains of HIV, the CDRH3 does still play a role 
in binding. One of the benefits of antibodies generated by MZ B cells may be that 
a shorter CDRH3 [85, 109] aids binding to gp120 by a germline CDRH2. A short 
CDRH3 in addition to the potentially enhanced immune responses driven by a 
MZ B cell response would suggest that an adjuvant eliciting responses from MZ 
B cells may be particularly beneficial to HIV vaccine development. 
 
Future directions 
Based on analyses of B cells in the HIV-ignorant repertoire, we now know 
that FO B cells are likely the dominant responders to gp120. Additionally, MZ B 
cells express IGHV segments that have been shown to generate protective 
antibodies in vivo. These antibodies were cloned from class-switched memory B 
cells, so the phenotype of the original B cells is unknown. Given that MZ B cells 
exhibit enhanced immunostimulatory potential for both the cellular and humoral 
arms of the immune system, preferentially targeting this subset to respond over 
the normally dominant FO B cell subset may lead to a more protective antibody 
response in a vaccine setting. 
The homology of human IGHV1-2*02 and mouse IGHV1-53 provides an 
opportunity to use mouse models to test HIV vaccines. Mouse reagents and 
genetically altered strains are plentiful, allowing for almost any conceivable 
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hypothesis to be tested. In order to parse out the response of different B cell 
subsets during a vaccine response, a sensitive and reliable readout must be 
developed. For our specific questions, this would be the tracking of IGHV1-53-
bearing B cells. One option is to make a heavy chain knock-in mouse to provide 
cells to track in an intact mouse. This approach would certainly be informative, 
but for the study of MZ B cell responses, which are intricately dependent on their 
physiological location, cell transfers will have caveats (Fig 4.5). Attempts were 
made during these studies to develop a new method using RT-PCR amplification 
of IGHV1-53 from bulk cell populations (Fig 4.18-4.20). This method may not be 
sensitive enough, as preexisting variation in IGHV proportions in individual mice 
appear to prevent this type of analysis. Classical means of following clonotypic 
responses are to perform hybridoma timecourses or generate an anti-idiotypic 
antibody. For our purposes, an anti-idiotypic antibody may not be appropriate, 
since the eventual goal is to induce somatic hypermutation in the CDRH regions, 
which could cause a loss of detection. Additionally, an appealing alternative to 
hybridomas is to perform deep sequencing on different cell populations during an 
immune response. With the power of Illumina sequencing millions of IGHV 
segments can be analyzed from sorted FO, MZ, plasmablasts, germinal center 
cells, etc, during different timepoints of the response. Proportions of IGHV1-53 in 
responding populations can be compared with different antigens and adjuvants, 
guiding vaccine design. With these sorts of tools in place, we could then track B 
cell subset and IGHV1-53 contributions to ADCC activity or neutralizing 
antibodies following immunization. 
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The challenges of HIV vaccine design are not trivial. After decades of 
research, there is still a struggle to produce an antigen that recapitulates the 
native trimer while directing antibody responses to vulnerable epitopes such as 
the CD4 binding site. Much work has been done comparing the efficacy of gp140 
trimers as immunogens to gp120 monomers [117, 175]. These trimers are 
assembled in a native confirmation, mimicking how gp120 would be presented on 
the surface of a virion. Interestingly, one trimer construct is stabilized by a C3d 
complement subunit. C3d-bound antigen can serve as an adjuvant in several 
ways. For naïve B cells, C3d can bind CD21 in complex with CD19 and CD81 on 
the surface of the cell to augment BCR signaling [176]. In this regard, CD21 
signaling could supplement weak cross-linking from sparse antigen availability on 
the surface of HIV. CD21 is expressed to a higher degree on MZ B cells than FO 
B cells, allowing us to potentially target this subset with this antigen. Additionally, 
subcapsular sinus macrophages shuttle opsonized antigens into the follicles to B 
cells for delivery to follicular dendritic cells (FDCs), aiding affinity maturation in 
germinal center responses [177]. 
The efficacy of these trimers may be improved by multimerization so that 
BCR crosslinking can be achieved. However, gp140 trimers will certainly elicit 
type-specific antibodies directed at the variable regions. Alternatively, the RSC3 
probe that was used to isolate VRC01, is a truncated form of gp120 with the 
variable loops removed and the CD4 binding site exposed. This RSC3 protein 
could also be multimerized to specifically target CD4 binding site-directed 
antibodies. The addition of a carefully selected adjuvant, such as a TLR agonist, 
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could feasibly preferentially target MZ B cell activation over dominant FO B cell 
responses to gp120. If IGHV1-53 or IGHV1-2*02-expressing MZ B cells can be 
brought into germinal centers to undergo somatic hypermutation, broadly 
neutralizing CD4 binding site antibodies may be generated (Fig 5.2). 
 
Figure 5.2: Schematic of a protective HIV vaccine strategy 
From the pool of potentially gp120-reactive naïve B cells, cells that have the 
potential to generate protective antibodies capable of protecting diverse strains of 
HIV, such as IGHV1-2*02 B cells, should be stimulated. This could be 
accomplished by focusing binding on the CD4 binding site epitope. Additionally, 
to stimulate MZ B cell responses, the antigen could be multivalent and 
administered with adjuvants such as TLR agonists or C3d. These adjuvants 
could encourage MZ B cells to interact with a wide range of cognate CD4 T cells 
to seed germinal centers. Addition of C3d as an adjuvant could enhance antigen 
delivery to follicular dendritic cells, driving somatic hypermutation. The result of 
these MZ B cell-seeded germinal centers could be high affinity memory B cells 
and plasma cells with mutated IGHV1-2*02 heavy chains, capable of neutralizing 
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